



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-091482
Article Type:	Original research
Date Submitted by the Author:	23-Jul-2024
Complete List of Authors:	<p>Shifti, Desalegn Markos; The University of Queensland, Child Health Research Centre, ; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)</p> <p>Al Imam, Mahmudul Hassan ; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit</p> <p>Maresco-Pennisi, Diane; The University of Queensland, Centre for Clinical Research</p> <p>Whitcombe, Renarta; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit,</p> <p>Sly, P.D.; The University of Queensland, Children's Health and Environment Program, Child Health Research Centre</p> <p>Munns, Craig; The University of Queensland, Child Health Research Centre; The University of Queensland, Faculty of Medicine</p> <p>Peters, Rachel ; Murdoch Children's Research Institute; University of Melbourne, Department of Paediatrics</p> <p>Khandaker, Gulam; The University of Queensland, Child Health Research Centre; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit</p> <p>Koplin, Jennifer J; The University of Queensland, Child Health Research Centre; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)</p>
Keywords:	Chronic Disease, EPIDEMIOLOGIC STUDIES, EPIDEMIOLOGY, Prevalence, Asthma < THORACIC MEDICINE, Emergency Service, Hospital

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

**Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents**

**Authors:** Desalegn Markos Shifti<sup>a,b</sup>, PhD, Mahmudul Hassan Al Imam<sup>c</sup>, PhD, Diane Maresco-Pennisi<sup>d</sup>, PhD, Renarta Whitcombe<sup>e</sup>, GDip, Peter D Sly<sup>e</sup>, MD, DSc, Craig F Munns<sup>a,f,g</sup>, PhD, Rachel L Peters<sup>h,i</sup>, PhD, Gulam Khandaker<sup>a,c</sup>, PhD, Jennifer J Koplin<sup>a,b,h</sup>, PhD

**Affiliations:**

<sup>a</sup>Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia

<sup>b</sup>Centre for Food and Allergy Research (CFAR), Murdoch Children's Research Institute, Parkville, VIC, Australia

<sup>c</sup>Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia

<sup>d</sup>Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia

<sup>e</sup>Children's Health and Environment Program, Child Health Research Centre, The University of Queensland, South Brisbane, Australia

<sup>f</sup>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

<sup>g</sup>Department of Endocrinology and Diabetes, Queensland Children's Hospital, Brisbane, QLD, Australia

<sup>h</sup>Murdoch Children's Research Institute, Parkville, VIC, Australia

<sup>i</sup>Department of Paediatrics, University of Melbourne, Parkville, Australia

**Email address:**

Desalegn Markos Shifti: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au)

Mahmudul Hassan Al Imam: [mahmudul.alimam@health.qld.gov.au](mailto:mahmudul.alimam@health.qld.gov.au)

Diane Maresco-Pennisi: [d.marescopennisi@uq.edu.au](mailto:d.marescopennisi@uq.edu.au)

Renarta Whitcombe: [Renarta.Whitcombe@health.qld.gov.au](mailto:Renarta.Whitcombe@health.qld.gov.au)

Peter D Sly: [p.sly@uq.edu.au](mailto:p.sly@uq.edu.au)

Craig F Munns: [c.munns@uq.edu.au](mailto:c.munns@uq.edu.au)

Rachel L Peters: [rachel.peters@mcri.edu.au](mailto:rachel.peters@mcri.edu.au)

Gulam Khandaker: [gulam.khandaker@health.qld.gov.au](mailto:gulam.khandaker@health.qld.gov.au)

Jennifer J Koplin: [j.koplin@uq.edu.au](mailto:j.koplin@uq.edu.au)

**Corresponding author:** Desalegn Markos Shifti. Email: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au); Level 6, 62 Graham Street, South Brisbane, QLD 4101, Australia.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

**Objective:** To examine the overall incidence rate and trends in Emergency Department (ED) presentations related to asthma and allergic diseases in regional Australia with a particular focus on First Nations Australians.

**Design:** A retrospective analysis of data from the Emergency Department Information System.

**Setting:** This study used data from 12 public hospitals in Central Queensland, Australia, a region encompassing regional, rural, and remote outback areas.

**Participants:** A total of 813,112 ED presentations between 2018 and 2023.

**Outcome measure:** Asthma and allergic diseases were identified using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes.

**Results:** There were 13,273 asthma and allergic disease-related ED presentations, with an overall prevalence of 1.6% (95% confidence interval (CI): 1.6, 1.7). There was a significantly higher incidence rate of asthma and allergic disease-related ED presentations among First Nations Australians at 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to 98.9 per 10,000 person-years (95% CI: 97.2, 100.8) among Australians of other descents. The incidence rates, with corresponding 95% CI, of the four most common cases among First Nations Australians and Australians of other descents, respectively, were as follows: asthma (87.8 (82.0, 93.8) and 40.2 (39.0, 41.3)), unspecified allergy (55.3 (50.8, 60.2) and 36.0 (34.9, 37.1)), atopic/allergic contact dermatitis (17.1 (14.6, 19.9) and 10.6 (10.0, 11.2)), and anaphylaxis (7.2 (5.6, 9.1) and 6.2 (5.7, 6.6)).

**Conclusion:** Our findings highlight a significantly higher rate of asthma and allergic disease-related ED presentations among First Nations Australians compared to Australians of other descents. This underscores the urgent need for targeted healthcare interventions integrating culturally appropriate approaches, alongside additional research to understand causality.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

**Keywords:** Allergic diseases; Asthma; First Nations Australians; Indigenous Australians; Aboriginal and Torres Strait Islander peoples; Australians of other descents; Emergency Department, Trend, Incidence, Central Queensland, Australia

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Strengths and limitations of the study**

- The study uses the most recent, large data set including First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas.
- The reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation.
- Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

## 76 Introduction

77 Chronic diseases including asthma and allergy, are a leading cause of premature death and morbidity  
78 globally<sup>1 2</sup> and constitute a growing public health concern.<sup>3-5</sup> It is estimated that by 2050, 50% of the  
79 world's population will be affected by allergies.<sup>1 6</sup> In Australia, often labelled as the 'allergy capital of  
80 the world',<sup>7</sup> allergy is currently estimated to affect 4.1 million people and is anticipated to undergo a  
81 70% surge, with affected individuals projected to reach 7.7 million (26.1%) by 2050.<sup>3</sup>

82 Allergic diseases exert considerable economic and social impact and negatively impact individuals' and  
83 families' day-to-day living as well as quality of life.<sup>8 9</sup> The overall economic cost of food allergy alone  
84 in the United States was estimated to be USD 24.8 billion annually or USD 4184 per child.<sup>10</sup> The total  
85 Medicare cost for out-of-hospital services related to food allergy in children aged 1 to 4 years in  
86 Melbourne, Australia alone was estimated at AUD 26.1 million annually.<sup>11</sup>

87 There are clear racial, ethnic, and socioeconomic disparities in allergic diseases worldwide.<sup>12-14</sup> Studies  
88 conducted on the burden of allergic disease in racially and ethnically structurally oppressed  
89 communities in Canada and the United States (US) showed an increased burden of allergic and atopic  
90 diseases among the Indigenous peoples of Canada.<sup>15 16</sup> Specifically, studies<sup>15 16</sup> reported a significantly  
91 higher prevalence of current eczema (25% among Indigenous children compared to 14.3% among non-  
92 Indigenous children), current allergic rhinitis (12.5% among Indigenous children compared to 0.0%  
93 among non-Indigenous children), environmental allergy (4.2% among Indigenous and 0.0% among  
94 non-Indigenous), and past asthma (16.7% among Indigenous children compared to 14.2% among non-  
95 Indigenous children). However, little is known about the prevalence of allergies and anaphylaxis in  
96 First Nations Australians.<sup>17</sup> In our study, the phrase 'First Nations Australians' respectfully refers to the  
97 Aboriginal and Torres Strait Islander peoples in Australia.<sup>18</sup>

98 In general, the burden of disease is 2.3 times higher among First Nations Australians,<sup>19</sup> and health  
99 outcomes are poorer when compared to Australians of other descents.<sup>20</sup> Asthma was the third most  
100 commonly reported long-term condition (16%) affecting First Nations Australians,<sup>21 22</sup> and First



1  
2  
3 101 Nations Australian children had a 2.3 times higher prevalence of asthma than Australian children of  
4  
5 102 other descents.<sup>23</sup> However, there has been little research into other types of allergic disease in First  
6  
7 103 Nations Australians.  
8  
9  
10 104 Existing evidence from other countries suggests that disparities in the prevalence of allergic diseases  
11  
12  
13 105 exist between rural and urban areas. For example, a study conducted in South Africa reported a higher  
14  
15 106 prevalence of self-reported allergies and a higher prevalence of objectively measured food allergy in  
16  
17 107 urban areas compared to rural areas.<sup>24 25</sup> This underscores the importance of conducting region-  
18  
19 108 specific studies to inform targeted interventions and healthcare strategies. There has been little  
20  
21  
22 109 research into allergic disease in regional and rural areas of Australia. The lack of comprehensive data  
23  
24 110 in these areas hinders our understanding of the unique factors influencing allergies in regional  
25  
26 111 settings, including distinct environmental exposures and lifestyle variations. Although some  
27  
28 112 evidence<sup>26</sup> suggests that certain allergies, including food allergies and eczema, may be less common  
29  
30 113 in Northern Australia based on self-report, region-specific further studies are required to inform  
31  
32  
33 114 targeted interventions and healthcare strategies.  
34  
35  
36 115 The current study endeavours to fill some of the existing evidence gaps by examining incidence rate  
37  
38 116 and trends of ED presentations related to asthma and allergic diseases, both collectively and  
39  
40 117 individually, among both First Nations Australians and Australians of other descents in Central  
41  
42 118 Queensland, which encompasses both regional and rural and remote areas, from 2018 to 2023.

43  
44  
45 119 **Methods**

46  
47  
48 120 We conducted a retrospective analysis of data from the Emergency Department Information System  
49  
50 121 (EDIS) of Public Hospitals in Central Queensland (CQ), a regional district of Queensland, Australia,  
51  
52 122 located in the central east region (the study area map can be found in online Supplemental Figure 1  
53  
54 123 1).<sup>27</sup> The map was developed using the digital boundary files from the Australian Bureau of Statistics.<sup>28</sup>  
55  
56 124 CQ encompasses rural and remote outback towns.<sup>29</sup> This analysis focused on the service catchment  
57  
58  
59 125 area of Central Queensland Hospital and Health Service (CQHHS) and included all patients presenting

to the emergency department. CQHHS operates 12 public hospitals across various regions. These include 1) Rockhampton, Mount Morgan, and Capricorn Coast, situated within Inner Regional Australia, 2) Gladstone, Biloela, Emerald, Baralaba, Moura, Theodore, and Blackwater, which fall under Outer Regional Australia, and 3) Woorabinda and Springsure, located in Remote Australia.<sup>30 31</sup> CQHHS also provides Aboriginal and Torres Strait Islander Health, Maternity services, CQ Cancer Care Services, Mental Health, Alcohol and Other Drugs Services, Oral Health and General Practitioner referrals.<sup>30</sup> In this analysis, we used data only from ED presentations. Data from the 2021 national census show that the CQ region was populated by 228,246 people.<sup>32</sup> There were 59,070 families in CQ; the median age was 38 years and 64% of the population was aged between 15–64 years.<sup>32</sup> Over seven per cent (7.2%) of the total population in CQ identify as First Nations Australians.<sup>32</sup>

We identified ED presentations related to asthma and allergic disease by using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes, as detailed in Supplemental Table 1. Given that not all asthma cases are necessarily allergic,<sup>33 34</sup> and considering that our dataset encompasses the ICD code J45.9, indicative of unspecified asthma, we presented asthma both independently and collectively with allergic diseases. This approach aims to clarify both the overall burden of asthma and allergic diseases collectively, as well as specific instances.

We described the overall asthma and allergic disease-related ED presentations using covariates available in the administrative data. These were self-reported indigenous status (Aboriginal and/or Torres Strait Islanders, which are categorised into First Nations Australians, and not-Indigenous and not stated, which are categorised into Australians of other descents<sup>35</sup>), sex (female and male and intersex (intersex were combined with male because there were only 106 (0.01%) individuals who identified themselves as intersex), age group in years ( $\leq 4$ , 5-14, 15-29, 30-44, 45-59, 60+), hospital (Baralaba, Biloela, Blackwater, Emerald, Gladstone, Mount Morgan, Moura, Rockhampton, Springsure, Theodore, Woorabinda, and Yeppoon) as indirect indicator of place of residence.

## Data management and statistical analysis

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Data for the period January 2018 to November 2023 were retrieved in a one-time extraction from the data sources, deidentified, replaced with unique codes, and securely stored. We described participants’ characteristics using frequency with per cent. P values were calculated using Pearson’s  $\chi^2$  test. The incidence rates, with 95% confidence intervals (CIs), assuming a Poisson distribution, were calculated as the number of new asthma and allergic disease-related ED presentations per year divided by the total population of Central Queensland at risk during the same period. The total population of Central Queensland at risk per year was estimated as the total population of Central Queensland as reported by the Australian Bureau of Statistics.<sup>36</sup> The comparison of incidence and trends of asthma and allergic disease-related ED presentations over time was assessed using Poisson regression, presented as incidence rate ratios (IRRs) with corresponding 95% CIs. We used the goodness-of-fit chi-squared test to assess whether the Poisson model adequately fit our data. All P-values for these tests were not statistically significant (data not presented), suggesting that the Poisson model reasonably fits the observed data. Incidence rates specific to overall, indigenous status, and other available covariates, as described above, were presented.

**Patient and public involvement**

Patients and/or the general public were not involved in the design, or conduct, or drafting of this secondary analysis.

**Results**

There were a total of 813,112 ED presentations between January 2018 and November 2023, ranging from 1,248 (0.1%) in Baralaba to 303,138 (37.3%) in Rockhampton (Supplemental Table 2).

**Background characteristics of patients presenting with asthma and allergic diseases**

Table 1 presents the background characteristics of patients presenting to the ED due to asthma and allergic diseases. Statistically significant differences were observed in overall asthma and allergic disease-related ED presentations, with a higher proportion among females (1.8%), children aged

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

175 between 5-14 (2.8%), children aged under five (2.5%), and across various hospital catchment areas  
176 (Table 1).

### 177 **Incidence rates of asthma and allergic disease-related ED presentations**

178 Overall, the rate of asthma and allergic disease-related ED presentations was 96.9 per 10,000 person-  
179 years (95% CI: 95.3, 98.6). There was a higher rate of asthma and allergic disease-related ED  
180 presentations among the First Nations Australians, which was 177.5 per 10,000 person-years (95% CI:  
181 169.3, 186.0), compared to the incidence rate among Australians of other descents, which was 98.9  
182 per 10,000 person-years (95% CI: 97.2, 100.8).

183 Table 2 illustrates the incidence rate of the specific case between 2018 and 2023. The four most  
184 common cases presenting to emergency departments were asthma (40.5/10,000 person-years, 95%  
185 CI: 39.4, 41.5), unspecified allergy (34.6/10,000 person-years, 95% CI: 33.6, 35.6), atopic/allergic  
186 contact dermatitis (10.3/10,000 person-years, 95% CI: 9.7, 10.8) and anaphylaxis and anaphylactic  
187 shock (5.8/10,000 person-years, 95% CI: 5.4, 6.2). There was a higher incidence rate of asthma,  
188 unspecified allergy, atopic/allergic contact dermatitis and allergic urticaria among First Nations  
189 Australians compared to Australians of other descents. No food allergy presentations were reported  
190 in our data (Table 2).

### 191 **Time trend of asthma and allergic disease-related ED presentations**

192 Figure 1 presents the time trend in the rates of asthma and allergic disease-related ED presentations  
193 in Central Queensland. Except for the notable increase observed between 2018 and 2019, collective  
194 asthma and allergic disease-related ED presentations among First Nations Australians remained  
195 relatively stable. These rates ranged from 132.3 per 10,000 person-year (95% CI: 115.3, 151.1) in 2018  
196 to 157.2 per 10,000 person-year in 2023 (95% CI: 138.6, 177.5;  $P=0.462$ ). Similarly, rates of asthma  
197 and allergic disease-related presentations among Australians of other descents were nearly stable,  
198 varying from 94.0 per 10000 person-year (95% CI: 89.8, 98.4) in 2018 and 88.6 per 10000 person-year  
199 (95% CI: 84.5, 92.9,  $p=0.846$ ) in 2023.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 2 shows the time trend of ED presentation rates related to asthma and allergic disease separately. There was a significant increase in the rate of allergic diseases among First Nations Australians over time ( $P$  value = 0.026). Except for the peak observed in 2019 among First Nations Australians, asthma-related ED presentations remained relatively stable over time in both First Nations Australians and Australians of other descents.

Table 3 presents the total incidence of asthma and allergic disease-related ED presentations over the study period by gender and age group. The incidence rate of asthma and allergic disease-related ED presentations remained stable across indigenous status, gender, and age groups, with one exception. Among children aged 4 years or younger, there was a significant decline in the overall incidence of asthma and allergic disease-related ED presentations (IRR = 0.94, 95% CI: 0.91, 0.97,  $P < 0.001$ ) (Table 3).

**Discussion**

To the best of our knowledge, this is the first study to examine asthma and allergic disease-related ED presentations among both First Nations Australians and Australians of other descents in an understudied region of Australia, which encompasses both rural and remote outback towns. There was a significant increase in the rate of allergic diseases among First Nations Australians between 2018 and 2023. First Nations Australians in CQ experienced a significant rise in allergic diseases, with higher rates of ED presentations compared to Australians of other descents. Asthma, unspecified allergies, atopic/allergic contact dermatitis, and anaphylaxis/anaphylactic shock were the most common conditions observed in the ED presentations, with higher rates among First Nations Australians compared to Australians of other descents.

The higher rate of ED presentations related to allergic disease among First Nations Australians was surprising given that allergic and atopic diseases have not been traditionally recognised as an important concern among First Nations Australians.<sup>37</sup> Nevertheless, there is currently a growing recognition of this issue. Our findings highlight a substantial and potentially increasing burden of

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

allergic disease among First Nations Australians living in a region encompassing regional, rural, and remote outback areas. This finding is in agreement with the findings of a study conducted in Canada and the US that showed an increased burden of allergic and atopic diseases among the Indigenous peoples of Canada.<sup>15</sup> Other previous studies conducted in the US and Australia, while lacking specific data on First Nations populations, also documented the existence of racial, ethnic, and socioeconomic disparities in food allergies.<sup>12-14</sup> Further studies are warranted to understand the underlying causes of these observed disparities.

There was a notable peak in recorded asthma-related ED presentations among First Nations Australians in 2019. This could be partially attributed to the bushfires that swept across Australia in 2019–20, also known as Black Summer, as asthma was one of the primary reasons for the ED presentations. Evidence shows that the national increase in emergency presentation and hospitalisation rates for asthma and chronic obstructive pulmonary disease (COPD) coincided with increased bushfire activity during the 2019–20 bushfire season.<sup>38</sup> Bushfire smoke exposure was significantly associated with an increased risk of respiratory morbidity and other health impacts.<sup>39 40</sup> The notable spike in recorded asthma-related ED presentations could also be ascribed to the notably vigorous flu season in 2019,<sup>41</sup> which is recognised as one of the triggers for an asthma attack.<sup>42</sup>

The primary reason for ED presentations was asthma, with a significantly higher incidence observed among First Nations Australians compared to Australians of other descents. Within our dataset, asthma cases could encompass both allergic and non-allergic variants. Literature documented that First Nations Australians were 1.6 times more likely to report having asthma in 2018-19 compared with Australians of other descents.<sup>43</sup> Another study that used birth, hospital and emergency data for all First Nations Australian children born between 2003 and 2012 in Western Australia reported that 2.7% of children had been hospitalised for asthma at least once between the ages of 1 and 4 years.<sup>44</sup> The higher incidence in asthma related ED presentation could be multifactorial including first time/unrecognised asthma, unmet medical need, unsuccessful/inadequate home management, medication

1  
2  
3 250 non-adherence, exacerbation triggered by environmental factors, including bushfire, environmental  
4  
5 251 pollution, and risky health behaviours such as smoking. Literature has documented that nearly half  
6  
7 252 (47%) of the respiratory disease burden among First Nations Australians in 2018 was linked to  
8  
9 253 smoking.<sup>45</sup> The lack of access to culturally appropriate asthma education and healthcare services could  
10  
11 254 also contribute to the higher incidence of asthma related ED presentations among First Nations  
12  
13 255 Australians.<sup>46</sup>  
14  
15  
16  
17 256 Atopic/allergic contact dermatitis ranked as the third most common cause for ED visits, with a higher  
18  
19 257 rate noted among First Nations Australians compared to Australians of other descents. A 5-year  
20  
21 258 retrospective audit of all outpatient encounters with a visiting dermatology specialist in the Kimberley  
22  
23 259 region of Western Australia reported that eczema/dermatitis was the primary condition seen in First  
24  
25 260 Nations Australians (19%) and third most common in Australians of other descents (17%).<sup>47</sup> Another  
26  
27 261 study conducted in Melbourne between 2009 and 2011 reported that 3.9% of ED presentations were  
28  
29 262 due to skin complaints, of which eczema/dermatitis was the fourth most common dermatological  
30  
31 263 condition although data on the indigenous status of the study population<sup>48</sup> was not reported. It is  
32  
33 264 documented that atopic dermatitis is associated with a higher risk of other atopic disorders, including  
34  
35 265 asthma, hay fever, food allergy, and eosinophilic esophagitis.<sup>49</sup> It is also a known risk factor for  
36  
37 266 streptococcal skin infection<sup>49-52</sup> and subsequent systemic and life-threatening complications including  
38  
39 267 sepsis, endocarditis, and bone and joint infections if left untreated.<sup>49 53-55</sup> For instance, a study at the  
40  
41 268 Wuchopperen Clinic in Cairns, Far North Queensland, found that 73.7% of children and youths treated  
42  
43 269 for skin infections tested positive for group A streptococcus.<sup>56</sup>  
44  
45  
46  
47  
48  
49 270 We found that anaphylaxis/anaphylactic shock was the fourth most common cause of allergy related  
50  
51 271 ED presentations. Previous studies conducted in Australia<sup>57 58</sup> documented an increase in the rate of  
52  
53 272 anaphylaxis over time although they lack data based on indigenous status. A study conducted in  
54  
55 273 Victoria reported that the causes of anaphylaxis-related ED presentations were foods (62%); drugs  
56  
57 274 (12%), insect venoms (8%), and other causes (4%).<sup>59</sup> The current study lacked data to specify the  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



275 causes of anaphylaxis/ anaphylactic shock. Interestingly, there were no food allergy presentations  
276 recorded in our data. However, it is possible that a substantial portion of the unspecified allergies,  
277 which was the second most frequent cause of ED presentations, may be linked to food allergies.  
278 Further studies are required to fill this evidence gap in our study area.

279 There was a twofold higher rate of allergic urticaria, which ranked as the fifth leading cause of ED  
280 visits, among First Nations Australians compared to their counterparts. A study conducted in Italy  
281 reported that acute urticaria in 1 year accounted for 1.01% of total ED visits and 1.2 admissions per  
282 day<sup>60</sup> and drugs, insect bites, foods and contact urticaria were the most common triggers identified.  
283 With a presumption that allergic urticaria that results in ED presentation in our study is acute urticaria  
284<sup>61</sup>, literature documented its risk factors including high population density,<sup>62</sup> personal<sup>63</sup> and parental  
285 history of allergic diseases,<sup>64 65</sup> poverty and lower socio-economic status.<sup>62 66</sup> Further studies are  
286 required to understand risk factors associated with allergic urticaria, particularly among First Nations  
287 Australians.

288 Strengths of the study include the use of the most recent, large data set including both First Nations  
289 Australians and Australians of other descents and all age groups from a study setting encompassing  
290 regional, rural, and remote outback areas. As a limitation, the reporting of ED presentations related  
291 to asthma and allergic disease relies on the ICD codes entered by physicians at the time of  
292 presentation. Our study specifically focused on asthma and allergic disease-related ED presentations  
293 and did not encompass all instances of acute asthma and allergic diseases in the general population  
294 which may visit health facilities in routes other than ED. Caution should be taken when generalising  
295 our results to the broader population, as they may not fully reflect the overall incidence of asthma  
296 and allergic diseases in the community but asthma and acute allergic disease resulting in ED visits only.  
297 Our analyses were limited to factors available in the administrative data, not comprehensively  
298 incorporating other important factors, including socioeconomic status, which encompasses  
299 education, financial resources, social standing, access to transportation, mobile phones, the internet,



1  
2  
3 300 housing conditions, and geographic location,<sup>67</sup> comorbidities, time of first allergy diagnosis, family  
4  
5 301 history of allergies, obesity/overweight, smoking status, and environmental factors among others. For  
6  
7 302 instance, literature has documented that social disadvantage impacts many aspects of allergic disease,  
8  
9  
10 303 including healthcare access, prevalence, and outcomes.<sup>12 68</sup> Therefore, further research is needed to  
11  
12 304 explore the overall incidence of asthma and allergic diseases, considering a comprehensive set of  
13  
14 305 potential confounders, to provide a more thorough understanding of both overall allergy incidence  
15  
16 306 and its associated factors. Also, it is important to note that our study relied on the accurate reporting  
17  
18  
19 307 of individuals' indigenous status in medical records.

20  
21  
22 308 **Conclusion**  
23  
24 309 Our findings highlight a significantly higher rate of asthma and allergic disease-related ED  
25  
26 310 presentations among First Nations Australians compared to Australians of other descents in Central  
27  
28 311 Queensland. This underscores the urgent need for further research to understand the causality and  
29  
30 312 targeted healthcare interventions integrating a culturally sensitive approach.

31  
32  
33 313 **Acknowledgements**  
34  
35  
36 314 We express our gratitude to Central Queensland Hospital and Health Service (CQHHS) for granting us  
37  
38 315 permission to use routinely collected hospital administrative data for our further analysis.

39  
40  
41 316 **Contributors**  
42  
43  
44 317 All authors (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) contributed to the design of the study and  
45  
46 318 the interpretation of data. DMS performed the data analysis and drafted the manuscript. All authors  
47  
48 319 (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) read, revised, and approved the final manuscript.

49  
50  
51 320 **Funding**  
52  
53  
54 321 PDS (GRT1193840), R.L.P. (GNT1160779), G.K. (2021/GNT2009873), and J.J.K. (GNT1158699) are  
55  
56 322 supported by NHMRC-funded fellowships. This study received no grant from any funding agency in  
57  
58 323 public, commercial or not-for-profit domains.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

324 **Conflict of interest**

325 All other authors declare no conflict of interest.

326 **Patient consent for publication**

327 Not required.

328 **Ethics approval**

329 We obtained ethics approval from the Human Research Ethics Committee (HREC) of the Central  
330 Queensland Hospital and Health Service (CQHHS) (Reference Id: 101806). Owing to the retrospective  
331 design of this study and its reliance on routinely collected hospital administrative data for medical  
332 services, seeking individual consent was deemed unnecessary.

333 **Data availability statement**

334 Data are not publicly available and may be obtained from a third party. Deidentified patient data can  
335 be requested from the Central Queensland Hospital and Health Service (CQHHS).

336 **ORCID iDs**

337 Desalegn Markos Shifti: <https://orcid.org/0000-0001-6638-6194>

References

1. Tanno LK, Demoly P. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. *Pediatric Allergy and Immunology* 2022;33:5-7.

2. WHO. Noncommunicable diseases [cited 11 April 2024]. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> accessed 2024 11 April.

3. Cook M, Douglass J, Mallon D, et al. The economic impact of allergic disease in Australia: not to be sneezed at. *ASCIA/Access Economics Report* 2007

4. Vale SL, Said M, Smith J, et al. Welcome back Kotter—developing a national allergy strategy for Australia. *World Allergy Organization Journal* 2022;15(11):100706.

5. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma research and practice* 2017;3:1-11.

6. Papadopoulos NG, Agache I, Bavbek S, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. *Clinical and translational allergy* 2012;2(1):1-23.

7. Parliament of Australia. Overview of allergies and anaphylaxis in Australia [cited 15 January 2024]. Available from: [https://www.aph.gov.au/Parliamentary\\_Business/Committees/House/Health\\_Aged\\_Care\\_and\\_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559](https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559) accessed 2024 15 January.

8. Bosnic-Anticevich S, Smith P, Abramson M, et al. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. *BMJ open* 2020;10(11):e038870.

9. McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. *Medical Journal of Australia* 2018;209(S2):S28-S33.

10. Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. *JAMA pediatrics* 2013;167(11):1026-31.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

11. Hua X, Dalziel K, Brettig T, et al. Out-of-hospital health care costs of childhood food allergy in Australia: A population-based longitudinal study. *Pediatric Allergy and Immunology* 2022;33(11):e13883.
12. Jiang J, Warren CM, Brewer A, et al. Racial, Ethnic, and Socioeconomic Differences in Food Allergies in the US. *JAMA Network Open* 2023;6(6):e2318162-e62.
13. Suaini NH, Loo EXL, Peters RL, et al. Children of Asian ethnicity in Australia have higher risk of food allergy and early-onset eczema than those in Singapore. *Allergy* 2021;76(10):3171-82.
14. Panjari M, Koplin J, Dharmage S, et al. Nut allergy prevalence and differences between Asian-born children and Australian-born children of Asian descent: a state-wide survey of children at primary school entry in Victoria, Australia. *Clinical & Experimental Allergy* 2016;46(4):602-09.
15. Jafri S, Janzen J, Kim R, et al. Burden of allergic disease in racial and ethnic structurally oppressed communities within Canada and the United States: a scoping review. *The Journal of Allergy and Clinical Immunology: In Practice* 2022;10(11):2995-3001.
16. Ahmed A, Hakim A, Becker A. Evaluation of eczema, asthma, allergic rhinitis and allergies among the grade-1 children of Iqaluit. *Allergy, Asthma & Clinical Immunology* 2018;14:1-14.
17. Courtney A, Lopez DJ, Lowe AJ, et al. Burden of disease and unmet needs in the diagnosis and management of atopic dermatitis in diverse skin types in Australia. *Journal of Clinical Medicine* 2023;12(11):3812.
18. AIHW. Profile of First Nations people [cited 17 January 2024]. Available from: <https://www.aihw.gov.au/reports/australias-welfare/profile-of-indigenous-australians> accessed 2024 17 January.
19. Australian Government Department of Health and Aged care AaTSIh. Status and determinants of Aboriginal and Torres Strait Islander health [cited 17 January 2024]. Available from: <https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants> accessed 2024 17 January.

1  
2  
3 390 20. Stephens C, Nettleton C, Porter J, et al. Indigenous peoples' health—why are they behind  
4  
5 391 everyone, everywhere? *The Lancet* 2005;366(9479):10-13.  
6  
7 392 21. ABS. National Aboriginal and Torres Strait Islander Health Survey: Statistics about long-term health  
8  
9 conditions, disability, lifestyle factors, physical harm and use of health services, 2018-19 [cited  
10 393 18 January 2024]. Available from: [https://www.abs.gov.au/statistics/people/aboriginal-and-](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release)  
11  
12 394 [torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release)  
13  
14 395 [survey/latest-release](https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander-peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release) accessed 2024 18 January.  
15  
16 396  
17  
18 397 22. AIHW. First Nations people with asthma [cited 18 January 2024]. Available from:  
19  
20 [https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma)  
21 398 [asthma](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma).  
22  
23 399  
24  
25 400 23. Al-Yaman F. The Australian Burden of Disease Study: impact and causes of illness and death in  
26  
27 Aboriginal and Torres Strait Islander people, 2011. *Public Health Research & Practice*  
28 401 2017;27(4)  
29  
30 402  
31  
32 403 24. Botha M, Basera W, Facey-Thomas HE, et al. Rural and urban food allergy prevalence from the  
33  
34 South African Food Allergy (SAFFA) study. *Journal of Allergy and Clinical Immunology*  
35 404 2019;143(2):662-68. e2.  
36  
37 405  
38  
39 406 25. Allen KJ, Koplin JJ. What can urban/rural differences in food allergy prevalence tell us about the  
40  
41 drivers of food allergy? *Journal of Allergy and Clinical Immunology* 2019;143(2):554-56.  
42  
43 408 26. Osborne NJ, Ukoumunne OC, Wake M, et al. Prevalence of eczema and food allergy is associated  
44  
45 with latitude in Australia. *Journal of allergy and clinical immunology* 2012;129(3):865-67.  
46 409  
47  
48 410 27. Khan A, Green K, Smoll N, et al. Roles, experiences and perspectives of the stakeholders of “10,000  
49  
50 Lives” smoking cessation initiative in Central Queensland: Findings from an online survey  
51 411 during COVID-19 situation. *Health Promotion Journal of Australia* 2022;33:316-26.  
52 412  
53  
54 413 28. Australian Bureau of Statistics. Digital boundary files; Australian Statistical Geography Standard  
55  
56 (ASGS) Edition 3. Reference period July 2021 - June 2026. [Available from:  
57 414 <https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs->  
58 415  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

- 416 [edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files](#) accessed 2024 31  
417 May.
- 418 29. Queensland Government. Central Queensland region [cited 23 January 2024]. Available from:  
419 [https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region)  
420 [queensland-region](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region) accessed 2024 23 January.
- 421 30. Queensland Government. Central Queensland Hospital and Health Service: Queensland Health;  
422 2016 [Available from: <https://www.health.qld.gov.au/cq> accessed 26/01/2019 2019.
- 423 31. Australian Government, Department of Health and Aged care. Health Workforce Locator [cited 08  
424 March 2024]. Available from: [https://www.health.gov.au/resources/apps-and-tools/health-](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app)  
425 [workforce-locator/app](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app) accessed 2024 08 March.
- 426 32. Australian Bureau of Statistics. Central Queensland: Australian Bureau of Statistics; 2022 [Available  
427 from: <https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023>.
- 428 33. Romanet-Manent S, Charpin D, Magnan A, et al. Allergic vs nonallergic asthma: what makes the  
429 difference? *Allergy* 2002;57(7):607-13.
- 430 34. Johansson S, Hourihane JB, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position  
431 statement from the EAACI nomenclature task force. *Allergy* 2001;56(9):813-24.
- 432 35. Queensland Health. Terminology Guide: for the use of 'First Nations' and 'Aboriginal' and 'Torres  
433 Strait Islander' peoples references [cited 09 April 2024]. Available from:  
434 [https://www.health.qld.gov.au/\\_data/assets/pdf\\_file/0031/147919/terminology.pdf](https://www.health.qld.gov.au/_data/assets/pdf_file/0031/147919/terminology.pdf)  
435 accessed 2024 09 April.
- 436 36. Australian Bureau of Statistics. Central Queensland: 2021 Census All persons QuickStats [cited 30  
437 January 2024]. Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308)  
438 [data/quickstats/2021/308](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308) accessed 2024 30 January.
- 439 37. Valery PC, Masters IB, Chang A. Asthma is not prevalent in Aboriginal and Torres Strait Islander  
440 children: a myth. *Journal of Paediatrics and Child Health* 2002;38(1):105-06.

1  
2  
3 441 38. AIHW. Data update: Short-term health impacts of the 2019–20 Australian bushfires [cited 16  
4  
5 442 January 2024]. Available from: [https://www.aihw.gov.au/reports/environment-and-](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about)  
6  
7 443 [health/data-update-health-impacts-2019-20-bushfires/contents/about](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about) accessed 2024 16  
8  
9 444 January  
10  
11  
12 445 39. Liu JC, Pereira G, Uhl SA, et al. A systematic review of the physical health impacts from non-  
13  
14 446 occupational exposure to wildfire smoke. *Environmental research* 2015;136:120-32.  
15  
16 447 40. Asthma Australia. Bushfire Smoke Impacts Survey 2019-2020- Bushfire Smoke: Are You Coping?  
17  
18 448 2020  
19  
20 449 41. Adegbija O, Walker J, Smoll N, et al. Notifiable diseases after implementation of COVID-19 public  
21  
22 450 health prevention measures in Central Queensland, Australia. *Communicable diseases*  
23  
24 451 *intelligence (2017: Online)* 2021  
25  
26 452 42. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma  
27  
28 453 exacerbations—A GA2LEN-DARE\* systematic review. *Allergy* 2011;66(4):458-68.  
29  
30 454 43. AIHW. Chronic respiratory conditions: Asthma [cited 16 January 2024]. Available from:  
31  
32 455 <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma> accessed 2024 16  
33  
34 456 January.  
35  
36 457 44. Brew B, Gibberd A, Marks GB, et al. Identifying preventable risk factors for hospitalised asthma in  
37  
38 458 young Aboriginal children: a whole-population cohort study. *Thorax* 2021;76(6):539-46.  
39  
40 459 45. AIHW. Australian Burden of Disease Study: Impact and causes of illness and death in Aboriginal  
41  
42 460 and Torres Strait Islander people 2018. *Canberra: AIHW* 2022  
43  
44 461 46. Brock C, McGuane J. Determinants of asthma in Indigenous Australians: insights from  
45  
46 462 epidemiology. *Austr Indigenous Health Bulletin* 2018;18(2):12-20.  
47  
48 463 47. Haggett MG, Tait CP. Five years of dermatological disease requiring specialist care in the Kimberley  
49  
50 464 region of Western Australia. *Australasian Journal of Dermatology* 2021;62(2):157-61.  
51  
52 465 48. Lai-Kwon J, Weiland TJ, Chong AH, et al. Which dermatological conditions present to an emergency  
53  
54 466 department in Australia? *Emergency Medicine International* 2014;2014



49. Silverberg JI. Comorbidities and the impact of atopic dermatitis. *Annals of Allergy, Asthma & Immunology* 2019;123(2):144-51.
50. Alexander H, Paller A, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *British Journal of Dermatology* 2020;182(6):1331-42.
51. Sugarman JL, Hersh AL, Okamura T, et al. A retrospective review of streptococcal infections in pediatric atopic dermatitis. *Pediatric dermatology* 2011;28(3):230-34.
52. Brook I, Frazier EH, Yeager JK. Microbiology of infected atopic dermatitis. *International journal of dermatology* 1996;35(11):791-93.
53. Benenson S, Zimhony O, Dahan D, et al. Atopic dermatitis—a risk factor for invasive *Staphylococcus aureus* infections: two cases and review. *The American Journal of Medicine* 2005;118(9):1048-51.
54. Patel D, Jahnke MN. Serious complications from *Staphylococcal aureus* in atopic dermatitis. *Pediatric dermatology* 2015;32(6):792-96.
55. Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology* 2019;80(4):904-12.
56. Valery PC, Wenitong M, Clements V, et al. Skin infections among Indigenous Australians in an urban setting in far North Queensland. *Epidemiology & Infection* 2008;136(8):1103-08.
57. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. *Journal of Allergy and Clinical Immunology* 2015;136(2):367-75.
58. Stiles SL, Sanfilippo FM, KS RL, et al. Contemporary trends in anaphylaxis burden and healthcare utilisation in Western Australia: A linked data study. *World Allergy Organization Journal* 2023;16(9):100818.



1  
2  
3 491 59. Drewett GP, Encena J, Gregory J, et al. Anaphylaxis in Victoria: presentations to emergency  
4  
5 492 departments, with a focus on drug-and antimicrobial-related cases. *Medical Journal of*  
6  
7 493 *Australia* 2022;216(10):520-24.  
8  
9  
10 494 60. Losappio L, Heffler E, Bussolino C, et al. Acute urticaria presenting in the emergency room of a  
11  
12 495 general hospital. *European Journal of Internal Medicine* 2014;25(2):147-50.  
13  
14 496 61. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international  
15  
16 497 EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis,  
17  
18 498 and management of urticaria. *Allergy* 2022;77(3):734-66.  
19  
20  
21 499 62. Jadhav R, Alcalá E, Sirota S, et al. Risk factors for acute urticaria in Central California. *International*  
22  
23 500 *Journal of Environmental Research and Public Health* 2021;18(7):3728.  
24  
25 501 63. Thomsen SF, Van der Sluis S, Kyvik KO, et al. Urticaria in monozygotic and dizygotic twins. *Journal*  
26  
27 502 *of allergy* 2012;2012  
28  
29 503 64. Hu Y, Chen Y, Liu S, et al. Breastfeeding duration modified the effects of neonatal and familial risk  
30  
31 504 factors on childhood asthma and allergy: a population-based study. *Respiratory research*  
32  
33 505 2021;22(1):1-11.  
34  
35 506 65. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. *Nature Reviews Disease Primers*  
36  
37 507 2022;8(1):61.  
38  
39 508 66. Gabrielle P, Hashim MJ, Shaughnessy C, et al. Global epidemiology of urticaria: increasing burden  
40  
41 509 among children, females and low-income regions. *Acta Dermato-Venereologica* 2021;101(4)  
42  
43 510 67. Australian Indigenous HealthInfoNet. Summary of respiratory diseases among Aboriginal and  
44  
45 511 Torres Strait Islander children *Perth, WA Australian Indigenous HealthInfoNet*  
46  
47 512 *healthinfoNetecueduau/respiratory* 2022  
48  
49 513 68. Perry TT, Grant TL, Dantzer JA, et al. Impact of socioeconomic factors on allergic diseases. *Journal*  
50  
51 514 *of Allergy and Clinical Immunology* 2023  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

**Table 1.** Background characteristics of patients presenting with asthma and allergic diseases compared to individuals presenting to ED for other reasons (N=813112)

Variable	Asthma and allergic disease-related ED presentations		P value
	No	Yes	
Indigenous status (n=812995)			
First Nations Australians	107099 (98.4)	1755 (1.6)	0.569
Australians of other descent /Not Stated	692623 (98.4)	11518 (1.6)	
Sex			
Female	397513 (98.2)	7395 (1.8)	< 0.001
Male and intersex	402325 (98.6)	5879 (1.4)	
Age group (Year, n=813111)			
≤4	78484 (97.5)	2018 (2.5)	< 0.001
5-14	87248 (97.2)	2540 (2.8)	
15-29	180778 (98.4)	2905 (1.6)	
30-44	148,015 (98.5)	2285 (1.5)	
45-59	129214 (98.4)	2051 (1.6)	
60+	176,098 (99.2)	1475 (0.8)	
Hospital			
Baralaba	1234(98.9)	14(1.1)	<0.001
Biloela	41009(98.0)	853(2.0)	
Blackwater	25048 (98.1)	474 (1.9)	
Emerald	83599(98.6)	1216 (1.4)	
Gladstone	203136(98.2)	3618(1.8)	
Mount Morgan	15972(98.1)	301(1.9)	
Moura	12457(98.1)	241(1.9)	
Rockhampton	298827(98.6)	4311(1.4)	
Springsure	7983(98.2)	144(1.8)	
Theodore	1414(98.7)	19(1.3)	
Woorabinda	12894(98.2)	239(1.8)	
Yeppoon	96265(98.1)	1844(1.9)	

ED= Emergency Department

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

521 **Table 2.** Incidence rate of asthma and allergic diseases from 2018 to 2023.

Asthma and allergic diseases	Asthma and specific type of allergy (per 10000 person-year with 95% CI)		
	First Nations Australians	Australians of other descent	Overall
Asthma*	87.8 (82.0, 93.8)	40.2 (39.0, 41.3)	40.5 (39.4, 41.5)
Unspecified allergy*	55.3 (50.8, 60.2)	36.0 (34.9, 37.1)	34.6 (33.6, 35.6)
Atopic/allergic contact dermatitis*	17.1 (14.6, 19.9)	10.6 (10.0, 11.2)	10.3 (9.7, 10.8)
Anaphylaxis and anaphylactic shock	7.2 (5.6, 9.1)	6.2 (5.7, 6.6)	5.8 (5.4, 6.2)
Allergic urticaria*	4.0 (2.9, 5.5)	2.3 (2.1, 2.6)	2.3 (2.0, 2.5)
Allergic conjunctivitis*	3.6 (2.5, 5.0)	2.4 (2.1, 2.7)	2.3 (2.1, 2.6)
Allergic rhinitis*	1.9 (1.2, 3.0)	0.7 (0.6, 0.9)	0.8 (0.6, 0.9)
Allergic purpura	0.5 (0.2, 1.2)	0.5 (0.4, 0.7)	0.5 (0.4,0.6)
Overall allergic diseases*, **	89.7 (83.9, 95.8)	58.8 (57.4, 60.2)	56.4 (55.2, 57.7)


522 \*P value < 0.05 when comparing the incidence rate per person-year between First Nations Australians  
523 and Australians of other descent, \*\*Overall allergic diseases encompass all specific allergic diseases,  
524 including unspecified allergy, atopic/allergic contact dermatitis, anaphylaxis, and anaphylactic shock,  
525 allergic urticaria, allergic conjunctivitis, allergic rhinitis, and allergic purpura but not asthma

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES) .

**Table 3.** Incidence of asthma and allergic disease-related ED presentations (per 10,000 person-years) from 2018 to 2023


Year	Asthma and allergic disease-related ED presentations							
	Sex		Age (Year)					
	Female	Male and intersex	0-4	5-14	15-29	30-44	45-59	60+
2018	101.2	78.2	281.6	111.9	99.0	75.0	64.5	47.9
2019	116.7	89.4	262.6	147.8	119.0	77.5	82.5	55.4
2020	105.4	80.7	208.9	105.0	108.9	98.3	80.5	44.7
2021	123.6	97.2	240.7	134.2	138.5	100.1	95.3	57.0
2022	111.9	86.9	222.3	134.2	135.6	84.2	74.5	46.3
2023	96.6	76.9	208.2	133.0	97.4	76.6	60.9	44.5
IRR (95% CI)	0.99 (0.95, 1.04)	1.001 (0.951, 1.053)	0.94 (0.91, 0.97)	1.02 (0.97, 1.06)	1.02 (0.97, 1.06)	1.01 (0.96, 1.06)	0.98 (0.93, 1.04)	0.98 (0.91, 1.05)
P value	0.824	0.974	<0.001	0.320	0.432	0.700	0.710	0.587

ED= Emergency Department, IRR= Incidence rate ratio, CI= Confidence interval



**Figure 1.** Incidence of both asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Ensignment Supérieur (ABES).



**Figure 2.** Separate incidence of asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Supplemental Table 1.** ICD-10-AM codes related to allergic conditions.

Condition	ICD-10-AM Code
Allergy, unspecified	T78.4, Z91.0
Allergic atopic dermatitis	L20, L20.8, L20.9
Allergic contact dermatitis	L23, L23.0-L23.9
Allergic conjunctivitis	H10.1, H10.2, H10.3, H10.4,
Allergic gastroenteritis	K52.2
Allergic purpura	D69.0
Allergic rhinitis	J30, J30.1, J30.2, J30.3, J30.4, J30.5
Allergic urticaria	L50.0, L50.8
Anaphylaxis	T78.0, T78.1, T78.2, T80.5, T88.6
Asthma	J45.0, J45.8, J45.9, J46
Food allergy	Y37.0-Y37.9, Y37.2, Y37.20, Y37.21, Y37.22, Y37.23, Y37.29, Y37.3, Y37.30, Y37.31, Y37.32, Y37.39, Y37.4, Y37.5


Enseignement Supérieur (ABES) .  
Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**Supplemental Table 2.** Emergency Department presentations at Public Hospitals in Central Queensland, 1 January 2018 to 30 November 2023 (N=813, 122)

Hospital	Year Frequency (%)						Total
	2018	2019	2020	2021	2022	2023	
Baralaba	X	X	X	237 (19.0)	547 (43.8)	464 (37.2)	1248 (100.0)
Biloela	6549 (15.6)	6394 (15.3)	7312 (17.5)	7268 (17.4)	7294 (17.4)	7045 (16.8)	41862 (100.0)
Blackwater	1207 (4.7)	5184 (20.3)	4453 (17.5)	4651 (18.2)	4752 (18.6)	5275 (20.7)	25522 (100.0)
Emerald	12320 (14.5)	13129 (15.5)	13110 (15.5)	16036 (18.9)	15639 (18.4)	1458 (17.2)	84815 (100.0)
Gladstone	31065 (15.0)	34340 (16.6)	36627 (17.7)	36349 (17.6)	36209 (17.5)	32164 (15.6)	206754 (100.0)
Mount Morgan	805 (4.9)	2925 (18.0)	2820 (17.3)	3280 (20.2)	3448 (21.2)	2995 (18.4)	16273 (100.0)
Moura	481 (3.8)	2158 (17.0)	2410 (19.0)	3118 (24.5)	2603 (20.5)	1928 (15.2)	12698 (100.0)
Rockhampton	47270 (15.5)	50522 (16.7)	49869 (16.5)	55777 (18.4)	52708 (17.4)	46992 (15.5)	303138 (100.0)
Springsure	337 (4.1)	1565 (19.3)	1697 (20.9)	1644 (20.2)	1535 (18.9)	1349 (16.6)	8127 (100.0)
Theodore	X	X	X	290 (20.2)	586 (40.9)	557 (38.9)	1433 (100.0)
Woorabinda	380 (2.9)	2107 (16.0)	2497 (19.0)	2476 (18.9)	2903 (22.1)	2770 (21.1)	13133 (100.0)
Yeppoon	14540 (14.8)	15017 (15.3)	15500 (15.8)	19797 (20.2)	17577 (17.9)	15678 (16.0)	98109 (100.0)
Total	114954 (14.1)	133341 (16.4)	136295 (16.8)	150923 (18.6)	145801 (17.9)	131798 (16.2)	813112 (100.0)

X= ED services were not available.





**Supplemental Figure 1.** Locator map of the study area.

**Source:** The map was developed using the digital boundary files from the Australian Bureau of Statistics.

# BMJ Open

## Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents

Journal:	BMJ Open
Manuscript ID	bmjopen-2024-091482.R1
Article Type:	Original research
Date Submitted by the Author:	15-Jan-2025
Complete List of Authors:	Shifti, Desalegn Markos; The University of Queensland, Child Health Research Centre, ; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR) Al Imam, Mahmudul Hassan ; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit Maresco-Pennisi, Diane; The University of Queensland, Centre for Clinical Research Whitcombe, Renarta; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit, Sly, P.D.; The University of Queensland, Children's Health and Environment Program, Child Health Research Centre Munns, Craig; The University of Queensland, Child Health Research Centre; The University of Queensland, Faculty of Medicine Peters, Rachel ; Murdoch Children's Research Institute; University of Melbourne, Department of Paediatrics Khandaker, Gulam; The University of Queensland, Child Health Research Centre; Central Queensland Hospital and Health Service, Central Queensland Public Health Unit Koplin, Jennifer J; The University of Queensland, Child Health Research Centre; Murdoch Children's Research Institute, Centre for Food and Allergy Research (CFAR)
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Emergency medicine, Epidemiology, Health services research, Public health, Immunology (including allergy)
Keywords:	Chronic Disease, EPIDEMIOLOGIC STUDIES, EPIDEMIOLOGY, Prevalence, Asthma < THORACIC MEDICINE, Emergency Service, Hospital

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Emergency Department presentations related to asthma and allergic diseases in Central Queensland, Australia: a comparative analysis between First Nations Australians and Australians of other descents**

**Authors:** Desalegn Markos Shifti<sup>a,b</sup>, PhD, Mahmudul Hassan Al Imam<sup>c</sup>, PhD, Diane Maresco-Pennisi<sup>d</sup>, PhD, Renarta Whitcombe<sup>c</sup>, GDip, Peter D Sly<sup>e</sup>, MD, DSc, Craig F Munns<sup>a,f,g</sup>, PhD, Rachel L Peters<sup>h,i</sup>, PhD, Gulam Khandaker<sup>a,c</sup>, PhD, Jennifer J Koplin<sup>a,b,h</sup>, PhD

**Affiliations:**

<sup>a</sup>Child Health Research Centre, The University of Queensland, South Brisbane, QLD, Australia

<sup>b</sup>Centre for Food and Allergy Research (CFAR), Murdoch Children’s Research Institute, Parkville, VIC, Australia

<sup>c</sup>Central Queensland Public Health Unit, Central Queensland Hospital and Health Service, Rockhampton, QLD, Australia

<sup>d</sup>Centre for Clinical Research, The University of Queensland, Brisbane, QLD, Australia

<sup>e</sup>Children’s Health and Environment Program, Child Health Research Centre, The University of Queensland, South Brisbane, Australia

<sup>f</sup>Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia

<sup>g</sup>Department of Endocrinology and Diabetes, Queensland Children’s Hospital, Brisbane, QLD, Australia

<sup>h</sup>Murdoch Children’s Research Institute, Parkville, VIC, Australia

<sup>i</sup>Department of Paediatrics, University of Melbourne, Parkville, Australia

**Email address:**

Desalegn Markos Shifti: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au)

Mahmudul Hassan Al Imam: [mahmudul.alimam@health.qld.gov.au](mailto:mahmudul.alimam@health.qld.gov.au)

Diane Maresco-Pennisi: [d.marescopennisi@uq.edu.au](mailto:d.marescopennisi@uq.edu.au)

Renarta Whitcombe: [Renarta.Whitcombe@health.qld.gov.au](mailto:Renarta.Whitcombe@health.qld.gov.au)

Peter D Sly: [p.sly@uq.edu.au](mailto:p.sly@uq.edu.au)

Craig F Munns: [c.munns@uq.edu.au](mailto:c.munns@uq.edu.au)

Rachel L Peters: [rachel.peters@mcri.edu.au](mailto:rachel.peters@mcri.edu.au)

Gulam Khandaker: [gulam.khandaker@health.qld.gov.au](mailto:gulam.khandaker@health.qld.gov.au)

Jennifer J Koplin: [j.koplin@uq.edu.au](mailto:j.koplin@uq.edu.au)

**Corresponding author:** Desalegn Markos Shifti. Email: [d.shifti@uq.edu.au](mailto:d.shifti@uq.edu.au); Level 6, 62 Graham Street, South Brisbane, QLD 4101, Australia.

## Abstract

**Objective:** To examine the overall incidence rate and trends in Emergency Department (ED) presentations related to asthma and allergic diseases in regional Australia with a particular focus on First Nations Australians.

**Design:** A retrospective analysis of data from the Emergency Department Information System.

**Setting:** This study used data from 12 public hospitals in Central Queensland, Australia, a region encompassing regional, rural, and remote outback areas.

**Participants:** A total of 813,112 ED presentations between 2018 and 2023.

**Outcome measure:** Asthma and allergic diseases were identified using the International Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes.

**Results:** There were 13,273 asthma and allergic disease-related ED presentations, with an overall prevalence of 1.6% (95% confidence interval (CI): 1.6, 1.7). There was a significantly higher incidence rate of asthma and allergic disease-related ED presentations among First Nations Australians at 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to 98.9 per 10,000 person-years (95% CI: 97.2, 100.8) among Australians of other descents. The incidence rates, with corresponding 95% CI, of the four most common cases among First Nations Australians and Australians of other descents, respectively, were as follows: asthma (87.8 (82.0, 93.8) and 40.2 (39.0, 41.3)), unspecified allergy (55.3 (50.8, 60.2) and 36.0 (34.9, 37.1)), atopic/allergic contact dermatitis (17.1 (14.6, 19.9) and 10.6 (10.0, 11.2)), and anaphylaxis (7.2 (5.6, 9.1) and 6.2 (5.7, 6.6)).

**Conclusion:** Our findings highlight a significantly higher rate of asthma and allergic disease-related ED presentations among First Nations Australians compared to Australians of other descents. This underscores the urgent need for targeted healthcare interventions integrating culturally appropriate approaches, alongside additional research to understand causality.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Keywords:** Allergic diseases; Asthma; First Nations Australians; Indigenous Australians; Aboriginal and Torres Strait Islander peoples; Australians of other descents; Emergency Department, Trend, Incidence, Central Queensland, Australia

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Enseignement Supérieur (ABES).

## Strengths and limitations of the study

- The study uses the most recent, large data set including First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas.
- The reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation.
- Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

76   **Introduction**

77   Chronic diseases including asthma and allergy, are a leading cause of premature death and morbidity

78   globally<sup>1 2</sup> and constitute a growing public health concern.<sup>3-5</sup> It is estimated that by 2050, 50% of the

79   world's population will be affected by allergies.<sup>1 6</sup> In Australia, often labelled as the ‘allergy capital of

80   the world’,<sup>7</sup> allergy is currently estimated to affect 4.1 million people and is anticipated to undergo a

81   70% surge, with affected individuals projected to reach 7.7 million (26.1%) by 2050.<sup>3</sup>

82   Allergic diseases exert considerable economic and social impact and negatively impact individuals’ and

83   families’ day-to-day living as well as quality of life.<sup>8 9</sup> The overall economic cost of food allergy alone

84   in the United States was estimated to be USD 24.8 billion annually or USD 4184 per child.<sup>10</sup> The total

85   Medicare cost for out-of-hospital services related to food allergy in children aged 1 to 4 years in

86   Melbourne, Australia alone was estimated at AUD 26.1 million annually.<sup>11</sup>

87   There are clear racial, ethnic, and socioeconomic disparities in allergic diseases worldwide.<sup>12-14</sup> Studies

88   conducted on the burden of allergic disease in racially and ethnically structurally oppressed

89   communities in Canada and the United States (US) showed an increased burden of allergic and atopic

90   diseases (eczema, allergic rhinitis and asthma) among the Indigenous peoples of Canada.<sup>15 16</sup> In

91   Australia, the burden of disease in general is 2.3 times higher among First Nations Australians,<sup>17</sup> and

92   health outcomes are poorer when compared to Australians of other descents.<sup>18</sup> Asthma was the

93   second most commonly reported long-term condition (16.6%) affecting First Nations Australians.<sup>19 20</sup>

94   After adjusting for age difference, First Nations Australians were 1.6 times more likely to report having

95   asthma compared to Australians of other descent.<sup>21</sup> However, there has been little research into other

96   types of allergic disease in First Nations Australians.<sup>22</sup> In our study, the phrase ‘First Nations

97   Australians’ respectfully refers to the Aboriginal and Torres Strait Islander peoples in Australia.<sup>23</sup>

98   Existing evidence from other countries suggests that disparities in the prevalence of allergic diseases

99   exist between rural and urban areas. For example, a study conducted in South Africa reported a higher

100   prevalence of self-reported allergies and a higher prevalence of objectively measured food allergy in



urban areas compared to rural areas.<sup>24 25</sup> This underscores the importance of conducting region-specific studies to inform targeted interventions and healthcare strategies. There has been little research into allergic disease in regional and rural areas of Australia. The lack of comprehensive data in these areas hinders our understanding of the unique factors influencing allergies in regional settings, including distinct environmental exposures and lifestyle variations. Although some evidence<sup>26</sup> suggests that certain allergies, including food allergies and eczema, may be less common in Northern Australia based on self-report, region-specific further studies are required to inform targeted interventions and healthcare strategies.

The current study endeavours to fill some of the existing evidence gaps by examining incidence rate and trends of ED presentations related to asthma and allergic diseases, both collectively and individually, among both First Nations Australians and Australians of other descents in Central Queensland, which encompasses both regional and rural and remote areas, from 2018 to 2023. The focus on asthma and allergic disease-related ED presentations in our study is guided by several key considerations. First, ED data provide a relatively accessible and reliable means to investigate asthma and allergic diseases without extensive logistical requirements. Moreover, ED data capture the burden of severe and life-threatening cases that necessitate immediate medical attention, highlighting the acute impact of these conditions. Such data are critical for identifying gaps in preventive care, timely access to treatment, and community health resources, particularly in regional, rural and remote areas. Furthermore, the acute care dimensions of asthma and allergic diseases, especially among Indigenous people in regional, remote and rural, are often overlooked in the literature. By addressing these aspects, our study aims to fill these gaps and complement existing prevalence-focused research.

## Methods

### Study design and settings

We conducted a retrospective analysis of routinely collected data from the Emergency Department Information System (EDIS) of Public Hospitals in Central Queensland (CQ), a regional district of

1  
2  
3 126 Queensland, Australia, located in the central east region (the study area map can be found in online  
4  
5 127 Supplemental Figure 1).<sup>27</sup> The map was developed using the digital boundary files from the Australian  
6  
7 128 Bureau of Statistics.<sup>28</sup> CQ encompasses rural and remote outback towns.<sup>29</sup> This study targeted the  
8  
9  
10 129 service catchment area of Central Queensland Hospital and Health Service (CQHHS) and included all  
11  
12 130 patients presenting to the emergency department. CQHHS operates 12 public hospitals across various  
13  
14 131 regions. These include 1) Rockhampton, Mount Morgan, and Capricorn Coast, situated within Inner  
15  
16 132 Regional Australia, 2) Gladstone, Biloela, Emerald, Baralaba, Moura, Theodore, and Blackwater, which  
17  
18  
19 133 fall under Outer Regional Australia, and 3) Woorabinda and Springsure, located in Remote Australia.<sup>30</sup>  
20  
21 134 <sup>31</sup> CQHHS also provides Aboriginal and Torres Strait Islander Health, Maternity services, CQ Cancer  
22  
23 135 Care Services, Mental Health, Alcohol and Other Drugs Services, Oral Health and General Practitioner  
24  
25 136 referrals.<sup>30</sup> Data from the 2021 national census show that the CQ region was populated by 228,246  
26  
27  
28 137 people.<sup>32</sup> There were 59,070 families in CQ; the median age was 38 years and 64% of the population  
29  
30 138 was aged between 15–64 years.<sup>32</sup> Over seven per cent (7.2%) of the total population in CQ identify as  
31  
32 139 First Nations Australians.<sup>32</sup>

34  
35 140 **Participants**

36  
37  
38 141 Our analysis included all ED presentation data from the CQHHS catchment areas, spanning January  
39  
40 142 2018 to November 2023, regardless of age or sex.

41  
42  
43 143 **Variables**

44  
45  
46 144 We described the overall asthma and allergic disease-related ED presentations using covariates  
47  
48 145 available in the administrative data. These were self-reported Indigenous status (Aboriginal and/or  
49  
50 146 Torres Strait Islanders, which are categorised into First Nations Australians, and not-Indigenous and  
51  
52 147 not stated, which are categorised into Australians of other descents<sup>33</sup>), sex (female, male, and  
53  
54 148 intersex), age group in years ( $\leq 4$ , 5-14, 15-29, 30-44, 45-59, 60+), hospital (Baralaba, Biloela,  
55  
56 149 Blackwater, Emerald, Gladstone, Mount Morgan, Moura, Rockhampton, Springsure, Theodore,  
57  
58 150 Woorabinda, and Yeppoon) as indirect indicator of place of residence.

## 151 Data source and measurement

152 Data were retrieved in a one-time extraction from the Business Analysis Decision Support (BADS)  
153 portal, deidentified, replaced with unique codes, and securely stored. The extraction was conducted  
154 by an experienced and expert data custodian following the CQHHS data extraction protocol. ED  
155 presentations related to asthma and allergic diseases were identified using the International  
156 Classification of Diseases-Tenth Revision-Australian Modification (ICD-10-AM) codes, as detailed in  
157 Supplemental Table 1. Given that not all asthma cases are necessarily allergic,<sup>34 35</sup> and considering that  
158 our dataset encompasses the ICD code J45.9, indicative of unspecified asthma, we presented asthma  
159 both independently and collectively with allergic diseases. This approach aims to clarify both the  
160 overall burden of asthma and allergic diseases collectively, as well as specific instances.

## 161 Statistical methods

162 We described participants' characteristics using frequency with per cent. P values were calculated  
163 using Pearson's  $\chi^2$  test, except in cases where the expected cell frequency was less than 5, where  
164 Fisher's Exact test was used. The incidence rates, with 95% confidence intervals (CIs), assuming a  
165 Poisson distribution, were calculated as the number of new asthma and allergic disease-related ED  
166 presentations per year divided by the total population of Central Queensland at risk during the same  
167 period. The total population of Central Queensland at risk per year was estimated as the total  
168 population of Central Queensland as reported by the Australian Bureau of Statistics.<sup>36</sup> The comparison  
169 of incidence and trends of asthma and allergic disease-related ED presentations over time was  
170 assessed using Poisson regression, presented as incidence rate ratios (IRRs) with corresponding 95%  
171 CIs. We used the goodness-of-fit chi-squared test to assess whether the Poisson model adequately fit  
172 our data. All P-values for these tests were not statistically significant (data not presented), suggesting  
173 that the Poisson model reasonably fits the observed data. Incidence rates specific to overall,  
174 indigenous status, and other available covariates, as described above, were presented.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Patient and public involvement**

Patients and/or the general public were not involved in the design, or conduct, or drafting of this secondary analysis.

**Results**

There were a total of 813,112 ED presentations between January 2018 and November 2023, ranging from 1,248 (0.1%) in Baralaba to 303,138 (37.3%) in Rockhampton (Supplemental Table 2).

**Background characteristics of patients presenting with asthma and allergic diseases**

Table 1 presents the background characteristics of patients presenting to the ED due to asthma and allergic diseases. Statistically significant differences were observed in overall asthma and allergic disease-related ED presentations compared to presentations for other reasons, with a higher proportion of asthma and allergic disease-related ED presentations among females, children aged between 5-14, children aged under five, and across various hospital catchment areas (Table 1).

**Incidence rates of asthma and allergic disease-related ED presentations**

Overall, the rate of asthma and allergic disease-related ED presentations was 96.9 per 10,000 person-years (95% CI: 95.3, 98.6). There was a higher rate of asthma and allergic disease-related ED presentations among the First Nations Australians, which was 177.5 per 10,000 person-years (95% CI: 169.3, 186.0), compared to the incidence rate among Australians of other descents, which was 98.9 per 10,000 person-years (95% CI: 97.2, 100.8).

Table 2 illustrates the incidence rate of the specific case between 2018 and 2023. The four most common cases presenting to emergency departments were asthma (40.5/10,000 person-years, 95% CI: 39.4, 41.5), unspecified allergy (34.6/10,000 person-years, 95% CI: 33.6, 35.6), atopic/allergic contact dermatitis (10.3/10,000 person-years, 95% CI: 9.7, 10.8) and anaphylaxis and anaphylactic shock (5.8/10,000 person-years, 95% CI: 5.4, 6.2). There was a higher incidence rate of asthma, unspecified allergy, atopic/allergic contact dermatitis and allergic urticaria among First Nations

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignement Supérieur (ABES).

199 Australians compared to Australians of other descents. No food allergy presentations were reported  
200 in our data (Table 2).

### 201 Time trend of asthma and allergic disease-related ED presentations

202 Figure 1 presents the time trend in the rates of asthma and allergic disease-related ED presentations  
203 in Central Queensland. Except for the notable increase observed between 2018 and 2019, collective  
204 asthma and allergic disease-related ED presentations among First Nations Australians remained  
205 relatively stable. These rates ranged from 132.3 per 10,000 person-year (95% CI: 115.3, 151.1) in 2018  
206 to 157.2 per 10,000 person-year in 2023 (95% CI: 138.6, 177.5;  $P=0.462$ ). Similarly, rates of asthma  
207 and allergic disease-related presentations among Australians of other descents were nearly stable,  
208 varying from 94.0 per 10000 person-year (95% CI: 89.8, 98.4) in 2018 and 88.6 per 10000 person-year  
209 (95% CI: 84.5, 92.9,  $p = 0.846$ ) in 2023.

210 Figure 2 shows the time trend of ED presentation rates related to asthma and allergic disease  
211 separately. There was a significant increase in the rate of allergic diseases among First Nations  
212 Australians over time ( $P \text{ value} = 0.026$ ). Except for the peak observed in 2019 among First Nations  
213 Australians, asthma-related ED presentations remained relatively stable over time in both First  
214 Nations Australians and Australians of other descents.

215 Table 3 presents the total incidence of asthma and allergic disease-related ED presentations over the  
216 study period by gender and age group. The incidence rate of asthma and allergic disease-related ED  
217 presentations remained stable across indigenous status, gender, and age groups, with one exception.  
218 Among children aged 4 years or younger, there was a significant decline in the overall incidence of  
219 asthma and allergic disease-related ED presentations (IRR = 0.94, 95% CI: 0.91, 0.97,  $P<0.001$ ) (Table  
220 3).

### 221 Discussion

1  
2  
3 222 To the best of our knowledge, this is the first study to examine asthma and allergic disease-related ED  
4  
5 223 presentations among both First Nations Australians and Australians of other descents in an  
6  
7 224 understudied region of Australia, which encompasses both rural and remote outback towns. There  
8  
9  
10 225 was a significant increase in the rate of allergic disease-related ED presentations among First Nations  
11  
12 226 Australians between 2018 and 2023. First Nations Australians in CQ experienced a significant rise in  
13  
14 227 allergic diseases, with higher rates of ED presentations compared to Australians of other descents.  
15  
16 228 Asthma, unspecified allergies, atopic/allergic contact dermatitis, and anaphylaxis/anaphylactic shock  
17  
18  
19 229 were the most common conditions observed in the ED presentations, with higher rates among First  
20  
21 230 Nations Australians compared to Australians of other descents.  
22  
23  
24 231 The higher rate of ED presentations related to allergic disease among First Nations Australians was  
25  
26 232 surprising given that allergic and atopic diseases have not been traditionally recognised as an  
27  
28 233 important concern among First Nations Australians.<sup>37</sup> Nevertheless, there is currently a growing  
29  
30 234 recognition of this issue. Our findings highlight a substantial and potentially increasing burden of  
31  
32  
33 235 allergic disease among First Nations Australians living in a region encompassing regional, rural, and  
34  
35 236 remote outback areas. This finding is in agreement with the findings of a study conducted in Canada  
36  
37 237 and the US that showed an increased burden of allergic and atopic diseases among the Indigenous  
38  
39 238 peoples of Canada.<sup>15</sup> Other previous studies conducted in the US and Australia, while lacking specific  
40  
41  
42 239 data on First Nations populations, also documented the existence of racial, ethnic, and socioeconomic  
43  
44 240 disparities in food allergies.<sup>12-14</sup> Further studies are warranted to understand the underlying causes of  
45  
46 241 these observed disparities.  
47  
48  
49 242 There was a notable peak in recorded asthma-related ED presentations among First Nations  
50  
51 243 Australians in 2019. This could be partially attributed to the bushfires that swept across Australia in  
52  
53 244 2019–20, also known as Black Summer, as asthma was one of the primary reasons for the ED  
54  
55  
56 245 presentations. Evidence shows that the national increase in emergency presentation and  
57  
58 246 hospitalisation rates for asthma and chronic obstructive pulmonary disease (COPD) coincided with  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

increased bushfire activity during the 2019–20 bushfire season.<sup>38</sup> Bushfire smoke exposure was significantly associated with an increased risk of respiratory morbidity and other health impacts.<sup>39 40</sup> The notable spike in recorded asthma-related ED presentations could also be ascribed to the notably vigorous flu season in 2019,<sup>41</sup> which is recognised as one of the triggers for an asthma attack.<sup>42</sup>

The primary reason for ED presentations was asthma, with a significantly higher incidence observed among First Nations Australians compared to Australians of other descents. Within our dataset, asthma cases could encompass both allergic and non-allergic variants. The higher incidence of asthma-related ED presentations could reflect either an increased prevalence of asthma or asthma exacerbations in First Nations Australians and/or an increased propensity of First Nations Australians to present to ED for asthma exacerbations due to socioeconomic or other factors. Literature documented that First Nations Australians were 1.6 times more likely to report having asthma in 2018–19 compared with Australians of other descents.<sup>43</sup> Another study that used birth, hospital and ED for all First Nations Australian children born between 2003 and 2012 in Western Australia reported that 2.7% of children had been hospitalised for asthma at least once between the ages of 1 and 4 years.<sup>44</sup>

The higher incidence of asthma-related ED presentation could be multifactorial including first time/unrecognised asthma, unmet medical need, unsuccessful/inadequate home management, medication non-adherence, exacerbation triggered by environmental factors, including bushfire, environmental pollution, and risky health behaviours such as smoking. Literature has documented that nearly half (47%) of the respiratory disease burden among First Nations Australians in 2018 was linked to smoking.<sup>45</sup> The lack of access to culturally appropriate asthma education and healthcare services could also contribute to the higher incidence of asthma-related ED presentations among First Nations Australians.<sup>46</sup>

Atopic/allergic contact dermatitis ranked as the third most common cause for ED visits, with a higher rate noted among First Nations Australians compared to Australians of other descents. A 5-year retrospective audit of all outpatient encounters with a visiting dermatology specialist in the Kimberley



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

region of Western Australia reported that eczema/dermatitis was the primary condition seen in First Nations Australians (19%) and third most common in Australians of other descents (17%).<sup>47</sup> Another study conducted in Melbourne between 2009 and 2011 reported that 3.9% of ED presentations were due to skin complaints, of which eczema/dermatitis was the fourth most common dermatological condition although data on the indigenous status of the study population<sup>48</sup> was not reported. It is documented that atopic dermatitis is associated with a higher risk of other atopic disorders, including asthma, hay fever, food allergy, and eosinophilic esophagitis.<sup>49</sup> It is also a known risk factor for streptococcal skin infection<sup>49-52</sup> and subsequent systemic and life-threatening complications including sepsis, endocarditis, and bone and joint infections if left untreated.<sup>49 53-55</sup> For instance, a study at the Wuchopperen Clinic in Cairns, Far North Queensland, found that 73.7% of children and youths treated for skin infections tested positive for group A streptococcus.<sup>56</sup>

We found that anaphylaxis/anaphylactic shock was the fourth most common cause of allergy related ED presentations. Previous studies conducted in Australia<sup>57 58</sup> documented an increase in the rate of anaphylaxis over time although they lack data based on indigenous status. A study conducted in Victoria reported that the causes of anaphylaxis-related ED presentations were foods (62%); drugs (12%), insect venoms (8%), and other causes (4%).<sup>59</sup> The current study lacked data to specify the causes of anaphylaxis/ anaphylactic shock. Interestingly, there were no food allergy presentations recorded in our data. However, it is possible that a substantial portion of the unspecified allergies, which was the second most frequent cause of ED presentations, may be linked to food allergies. Further studies are required to fill this evidence gap in our study area.

There was a twofold higher rate of allergic urticaria-related ED presentations, which ranked as the fifth leading cause of ED visits, among First Nations Australians compared to their counterparts. A study conducted in Italy reported that acute urticaria in 1 year accounted for 1.01% of total ED visits and 1.2 admissions per day <sup>60</sup> and drugs, insect bites, foods and contact urticaria were the most common triggers identified. With a presumption that allergic urticaria that results in ED presentation

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)



in our study is acute urticaria<sup>61</sup>, literature documented its risk factors including high population density,<sup>62</sup> personal<sup>63</sup> and parental history of allergic diseases,<sup>64 65</sup> poverty and lower socio-economic status.<sup>62 66</sup> Further studies are required to understand risk factors associated with allergic urticaria, particularly among First Nations Australians.

Strengths of the study include the use of the most recent, large data set including both First Nations Australians and Australians of other descents and all age groups from a study setting encompassing regional, rural, and remote outback areas. As a limitation, the reporting of ED presentations related to asthma and allergic disease relies on the ICD codes entered by physicians at the time of presentation. Our study specifically focused on asthma and allergic disease-related ED presentations and did not encompass all instances of acute asthma and allergic diseases in the general population which may visit health facilities in routes other than ED. Caution should be taken when generalising our results to the broader population, as they may not fully reflect the overall incidence of asthma and allergic diseases in the community but asthma and acute allergic disease resulting in ED visits only. Our analyses were limited to factors available in the administrative data, not comprehensively incorporating other important factors, including socioeconomic status, which encompasses education, financial resources, social standing, access to transportation, mobile phones, the internet, housing conditions, and geographic location,<sup>67</sup> comorbidities, time of first allergy diagnosis, family history of allergies, obesity/overweight, smoking status, and environmental factors among others. For instance, literature has documented that social disadvantage impacts many aspects of allergic disease, including healthcare access, prevalence, and outcomes.<sup>12 68</sup> Therefore, further research is needed to explore the overall incidence of asthma and allergic diseases, considering a comprehensive set of potential confounders, to provide a more thorough understanding of both overall allergy incidence and its associated factors. Also, it is important to note that our study relied on the accurate reporting of individuals' indigenous status in medical records.

## Conclusion

1  
2  
3 322 Our findings highlight a significantly higher rate of asthma and allergic disease-related ED  
4  
5 323 presentations among First Nations Australians compared to Australians of other descents in Central  
6  
7 324 Queensland. This underscores the urgent need for further research to understand the causality and  
8  
9  
10 325 targeted healthcare interventions integrating a culturally sensitive approach.

11  
12  
13 326 **Acknowledgements**

14  
15  
16 327 We express our gratitude to Central Queensland Hospital and Health Service (CQHHS) for granting us  
17  
18 328 permission to use routinely collected hospital administrative data for our further analysis.

19  
20  
21 329 **Contributors**

22  
23  
24 330 All authors (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) contributed to the design of the study and  
25  
26 331 the interpretation of data. DMS performed the data analysis and drafted the manuscript. All authors  
27  
28 332 (DMS, MHA, DM, RW, PDS, CFM, RLP, GK, JJK) read, revised, and approved the final manuscript. DMS  
29  
30 333 acted as the guarantor.

31  
32  
33 334 **Funding**

34  
35  
36 335 DMS is supported by a Postdoctoral Fellowship funded through the Centre for Food Allergy Research  
37  
38 336 Centre of Research Excellence (CFAR3 2023-2028\_NH&MRC GNT 2015724). PDS (GRT1193840), R.L.P.  
39  
40 337 (GNT1160779), G.K. (2021/GNT2009873), and J.J.K. (GNT1158699) are supported by NHMRC-funded  
41  
42 338 fellowships. This study received no grant from any funding agency in public, commercial or not-for-  
43  
44 339 profit domains.

45  
46  
47  
48 340 **Competing interests**

49  
50  
51 341 All other authors have no competing interest to declare.

52  
53  
54 342 **Patient consent for publication**

55  
56  
57 343 Not required.

58  
59  
60 344 **Ethics approval**

345 We obtained ethics approval from the Human Research Ethics Committee (HREC) of the Central  
346 Queensland Hospital and Health Service (CQHHS) (Reference Id: 101806). Owing to the retrospective  
347 design of this study and its reliance on routinely collected hospital administrative data for medical  
348 services, seeking individual consent was deemed unnecessary.

#### 349 **Data availability statement**

350 Data are not publicly available and may be obtained from a third party. Deidentified patient data can  
351 be requested from the Central Queensland Hospital and Health Service (CQHHS).

#### 352 **ORCID iDs**

353 Desalegn Markos Shifti: <https://orcid.org/0000-0001-6638-6194>

References

1. Tanno LK, Demoly P. Allergy in the World Health Organization's International Classification of Diseases (ICD)-11. *Pediatric Allergy and Immunology* 2022;33:5-7.

2. WHO. Noncommunicable diseases [cited 11 April 2024]. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases> accessed 2024 11 April.

3. Cook M, Douglass J, Mallon D, et al. The economic impact of allergic disease in Australia: not to be sneezed at. *ASCIA/Access Economics Report* 2007

4. Vale SL, Said M, Smith J, et al. Welcome back Kotter—developing a national allergy strategy for Australia. *World Allergy Organization Journal* 2022;15(11):100706.

5. Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. *Asthma research and practice* 2017;3:1-11.

6. Papadopoulos NG, Agache I, Bavbek S, et al. Research needs in allergy: an EAACI position paper, in collaboration with EFA. *Clinical and translational allergy* 2012;2(1):1-23.

7. Parliament of Australia. Overview of allergies and anaphylaxis in Australia [cited 15 January 2024]. Available from: [https://www.aph.gov.au/Parliamentary\\_Business/Committees/House/Health\\_Aged\\_Care\\_and\\_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559](https://www.aph.gov.au/Parliamentary_Business/Committees/House/Health_Aged_Care_and_Sport/Allergiesandanaphylaxis/Report/section?id=committees%2Freportrep%2F024422%2F72559) accessed 2024 15 January.

8. Bosnic-Anticevich S, Smith P, Abramson M, et al. Impact of allergic rhinitis on the day-to-day lives of children: insights from an Australian cross-sectional study. *BMJ open* 2020;10(11):e038870.

9. McDonald VM, Hiles SA, Jones KA, et al. Health-related quality of life burden in severe asthma. *Medical Journal of Australia* 2018;209(S2):S28-S33.

10. Gupta R, Holdford D, Bilaver L, et al. The economic impact of childhood food allergy in the United States. *JAMA pediatrics* 2013;167(11):1026-31.

- 381 11. Hua X, Dalziel K, Brettig T, et al. Out-of-hospital health care costs of childhood food allergy in  
 382 Australia: A population-based longitudinal study. *Pediatric Allergy and Immunology*  
 383 2022;33(11):e13883.
- 384 12. Jiang J, Warren CM, Brewer A, et al. Racial, Ethnic, and Socioeconomic Differences in Food  
 385 Allergies in the US. *JAMA Network Open* 2023;6(6):e2318162-e62.
- 386 13. Suaini NH, Loo EXL, Peters RL, et al. Children of Asian ethnicity in Australia have higher risk of  
 387 food allergy and early-onset eczema than those in Singapore. *Allergy* 2021;76(10):3171-82.
- 388 14. Panjari M, Koplin J, Dharmage S, et al. Nut allergy prevalence and differences between  
 389 Asian-born children and Australian-born children of Asian descent: a state-wide survey of  
 390 children at primary school entry in Victoria, Australia. *Clinical & Experimental Allergy*  
 391 2016;46(4):602-09.
- 392 15. Jafri S, Janzen J, Kim R, et al. Burden of allergic disease in racial and ethnic structurally oppressed  
 393 communities within Canada and the United States: a scoping review. *The Journal of Allergy*  
 394 *and Clinical Immunology: In Practice* 2022;10(11):2995-3001.
- 395 16. Ahmed A, Hakim A, Becker A. Evaluation of eczema, asthma, allergic rhinitis and allergies among  
 396 the grade-1 children of Iqaluit. *Allergy, Asthma & Clinical Immunology* 2018;14:1-14.
- 397 17. Australian Government Department of Health and Aged care. Status and determinants of  
 398 Aboriginal and Torres Strait Islander health [cited 17 January 2024]. Available from:  
 399 [https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-](https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants)  
 400 [determinants](https://www.health.gov.au/topics/aboriginal-and-torres-strait-islander-health/status-and-determinants) accessed 2024 17 January.
- 401 18. Stephens C, Nettleton C, Porter J, et al. Indigenous peoples' health—why are they behind  
 402 everyone, everywhere? *The Lancet* 2005;366(9479):10-13.
- 403 19. ABS. National Aboriginal and Torres Strait Islander Health Survey: Statistics about long-term  
 404 health conditions, disability, lifestyle factors, physical harm and use of health services, 2018-  
 405 19 [cited 18 January 2024]. Available from:  
 406 <https://www.abs.gov.au/statistics/people/aboriginal-and-torres-strait-islander->

1  
2  
3 407 [peoples/national-aboriginal-and-torres-strait-islander-health-survey/latest-release](#) accessed  
4  
5 408 2024 18 January.  
6  
7  
8 409 20. AIHW. First Nations people with asthma [cited 18 January 2024]. Available from:  
9  
10 410 [https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-](https://www.aihw.gov.au/reports/chronic-respiratory-conditions/first-nations-people-with-asthma)  
11 [asthma](#).  
12 411  
13  
14 412 21. AIHW. Chronic respiratory conditions: First Nations people with Asthma [cited 04 April 2024].  
15  
16 Available from: <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma>  
17 413  
18 accessed 2024 04 April.  
19 414  
20  
21 415 22. Courtney A, Lopez DJ, Lowe AJ, et al. Burden of disease and unmet needs in the diagnosis and  
22  
23 416 management of atopic dermatitis in diverse skin types in Australia. *Journal of Clinical*  
24  
25 417 *Medicine* 2023;12(11):3812.  
26  
27  
28 418 23. AIHW. Profile of First Nations people [cited 17 January 2024]. Available from:  
29  
30 419 <https://www.aihw.gov.au/reports/australias-welfare/profile-of-indigenous-australians>  
31  
32 420 accessed 2024 17 January.  
33  
34 421 24. Botha M, Basera W, Facey-Thomas HE, et al. Rural and urban food allergy prevalence from the  
35  
36 422 South African Food Allergy (SAFFA) study. *Journal of Allergy and Clinical Immunology*  
37  
38 423 2019;143(2):662-68. e2.  
39  
40  
41 424 25. Allen KJ, Koplin JJ. What can urban/rural differences in food allergy prevalence tell us about the  
42  
43 425 drivers of food allergy? *Journal of Allergy and Clinical Immunology* 2019;143(2):554-56.  
44  
45 426 26. Osborne NJ, Ukoumunne OC, Wake M, et al. Prevalence of eczema and food allergy is associated  
46  
47 427 with latitude in Australia. *Journal of allergy and clinical immunology* 2012;129(3):865-67.  
48  
49 428 27. Khan A, Green K, Smoll N, et al. Roles, experiences and perspectives of the stakeholders of  
50  
51 429 “10,000 Lives” smoking cessation initiative in Central Queensland: Findings from an online  
52  
53 430 survey during COVID-19 situation. *Health Promotion Journal of Australia* 2022;33:316-26.  
54  
55 431 28. Australian Bureau of Statistics. Digital boundary files; Australian Statistical Geography Standard  
56  
57 432 (ASGS) Edition 3. Reference period July 2021 - June 2026. [Available from:  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

- 433 <https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs->  
 434 [edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files](https://www.abs.gov.au/statistics/standards/australian-statistical-geography-standard-asgs-edition-3/jul2021-jun2026/access-and-downloads/digital-boundary-files) accessed 2024 31  
 435 May.
- 436 29. Queensland Government. Central Queensland region [cited 23 January 2024]. Available from:  
 437 [https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region)  
 438 [queensland-region](https://teach.qld.gov.au/teach-in-queensland-state-schools/our-schools/central-queensland-region) accessed 2024 23 January.
- 439 30. Queensland Government. Central Queensland Hospital and Health Service: Queensland Health;  
 440 2016 [Available from: <https://www.health.qld.gov.au/cq> accessed 26/01/2019 2019.
- 441 31. Australian Government, Department of Health and Aged care. Health Workforce Locator [cited  
 442 08 March 2024]. Available from: [https://www.health.gov.au/resources/apps-and-](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app)  
 443 [tools/health-workforce-locator/app](https://www.health.gov.au/resources/apps-and-tools/health-workforce-locator/app) accessed 2024 08 March.
- 444 32. Australian Bureau of Statistics. Central Queensland: Australian Bureau of Statistics; 2022  
 445 [Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023)  
 446 [data/quickstats/2021/3082023](https://www.abs.gov.au/census/find-census-data/quickstats/2021/3082023).
- 447 33. Queensland Health. Terminology Guide: for the use of 'First Nations' and 'Aboriginal' and  
 448 'Torres Strait Islander' peoples references [cited 09 April 2024]. Available from:  
 449 [https://www.health.qld.gov.au/ data/assets/pdf file/0031/147919/terminology.pdf](https://www.health.qld.gov.au/data/assets/pdf_file/0031/147919/terminology.pdf)  
 450 accessed 2024 09 April.
- 451 34. Romanet-Manent S, Charpin D, Magnan A, et al. Allergic vs nonallergic asthma: what makes the  
 452 difference? *Allergy* 2002;57(7):607-13.
- 453 35. Johansson S, Hourihane JB, Bousquet J, et al. A revised nomenclature for allergy: an EAACI  
 454 position statement from the EAACI nomenclature task force. *Allergy* 2001;56(9):813-24.
- 455 36. Australian Bureau of Statistics. Central Queensland: 2021 Census All persons QuickStats [cited 30  
 456 January 2024]. Available from: [https://www.abs.gov.au/census/find-census-](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308)  
 457 [data/quickstats/2021/308](https://www.abs.gov.au/census/find-census-data/quickstats/2021/308) accessed 2024 30 January.



1  
2  
3 458 37. Valery PC, Masters IB, Chang A. Asthma is not prevalent in Aboriginal and Torres Strait Islander  
4  
5 459 children: a myth. *Journal of Paediatrics and Child Health* 2002;38(1):105-06.  
6  
7 460 38. AIHW. Data update: Short-term health impacts of the 2019–20 Australian bushfires [cited 16  
8  
9 461 January 2024]. Available from: [https://www.aihw.gov.au/reports/environment-and-](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about)  
10  
11 462 [health/data-update-health-impacts-2019-20-bushfires/contents/about](https://www.aihw.gov.au/reports/environment-and-health/data-update-health-impacts-2019-20-bushfires/contents/about) accessed 2024 16  
12  
13 463 January  
14  
15 464 39. Liu JC, Pereira G, Uhl SA, et al. A systematic review of the physical health impacts from non-  
16  
17 465 occupational exposure to wildfire smoke. *Environmental research* 2015;136:120-32.  
18  
19 466 40. Asthma Australia. Bushfire Smoke Impacts Survey 2019-2020- Bushfire Smoke: Are You Coping?  
20  
21 467 2020  
22  
23 468 41. Adegbija O, Walker J, Smoll N, et al. Notifiable diseases after implementation of COVID-19 public  
24  
25 469 health prevention measures in Central Queensland, Australia. *Communicable diseases*  
26  
27 470 *intelligence* (2017: Online) 2021  
28  
29 471 42. Papadopoulos NG, Christodoulou I, Rohde G, et al. Viruses and bacteria in acute asthma  
30  
31 472 exacerbations—A GA2LEN-DARE\* systematic review. *Allergy* 2011;66(4):458-68.  
32  
33 473 43. AIHW. Chronic respiratory conditions: Asthma [cited 16 January 2024]. Available from:  
34  
35 474 <https://www.aihw.gov.au/reports/chronic-respiratory-conditions/asthma> accessed 2024 16  
36  
37 475 January.  
38  
39 476 44. Brew B, Gibberd A, Marks GB, et al. Identifying preventable risk factors for hospitalised asthma in  
40  
41 477 young Aboriginal children: a whole-population cohort study. *Thorax* 2021;76(6):539-46.  
42  
43 478 45. AIHW. Australian Burden of Disease Study: Impact and causes of illness and death in Aboriginal  
44  
45 479 and Torres Strait Islander people 2018. *Canberra: AIHW* 2022  
46  
47 480 46. Brock C, McGuane J. Determinants of asthma in Indigenous Australians: insights from  
48  
49 481 epidemiology. *Austr Indigenous Health Bulletin* 2018;18(2):12-20.  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).



47. Haggett MG, Tait CP. Five years of dermatological disease requiring specialist care in the Kimberley region of Western Australia. *Australasian Journal of Dermatology* 2021;62(2):157-61.
48. Lai-Kwon J, Weiland TJ, Chong AH, et al. Which dermatological conditions present to an emergency department in Australia? *Emergency Medicine International* 2014;2014
49. Silverberg JI. Comorbidities and the impact of atopic dermatitis. *Annals of Allergy, Asthma & Immunology* 2019;123(2):144-51.
50. Alexander H, Paller A, Traidl-Hoffmann C, et al. The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group. *British Journal of Dermatology* 2020;182(6):1331-42.
51. Sugarman JL, Hersh AL, Okamura T, et al. A retrospective review of streptococcal infections in pediatric atopic dermatitis. *Pediatric dermatology* 2011;28(3):230-34.
52. Brook I, Frazier EH, Yeager JK. Microbiology of infected atopic dermatitis. *International journal of dermatology* 1996;35(11):791-93.
53. Benenson S, Zimhony O, Dahan D, et al. Atopic dermatitis—a risk factor for invasive *Staphylococcus aureus* infections: two cases and review. *The American Journal of Medicine* 2005;118(9):1048-51.
54. Patel D, Jahnke MN. Serious complications from *Staphylococcus aureus* in atopic dermatitis. *Pediatric dermatology* 2015;32(6):792-96.
55. Serrano L, Patel KR, Silverberg JI. Association between atopic dermatitis and extracutaneous bacterial and mycobacterial infections: a systematic review and meta-analysis. *Journal of the American Academy of Dermatology* 2019;80(4):904-12.
56. Valery PC, Wenitong M, Clements V, et al. Skin infections among Indigenous Australians in an urban setting in far North Queensland. *Epidemiology & Infection* 2008;136(8):1103-08.
57. Mullins RJ, Dear KB, Tang ML. Time trends in Australian hospital anaphylaxis admissions in 1998-1999 to 2011-2012. *Journal of Allergy and Clinical Immunology* 2015;136(2):367-75.

1  
2  
3 508 58. Stiles SL, Sanfilippo FM, KS RL, et al. Contemporary trends in anaphylaxis burden and healthcare  
4  
5 509 utilisation in Western Australia: A linked data study. *World Allergy Organization Journal*  
6  
7 510 2023;16(9):100818.  
8  
9  
10 511 59. Drewett GP, Encena J, Gregory J, et al. Anaphylaxis in Victoria: presentations to emergency  
11  
12 512 departments, with a focus on drug-and antimicrobial-related cases. *Medical Journal of*  
13  
14 513 *Australia* 2022;216(10):520-24.  
15  
16 514 60. Losappio L, Heffler E, Bussolino C, et al. Acute urticaria presenting in the emergency room of a  
17  
18 515 general hospital. *European Journal of Internal Medicine* 2014;25(2):147-50.  
19  
20  
21 516 61. Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international  
22  
23 517 EAACI/GA<sup>2</sup>LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis,  
24  
25 518 and management of urticaria. *Allergy* 2022;77(3):734-66.  
26  
27  
28 519 62. Jadhav R, Alcala E, Sirota S, et al. Risk factors for acute urticaria in Central California.  
29  
30 520 *International Journal of Environmental Research and Public Health* 2021;18(7):3728.  
31  
32 521 63. Thomsen SF, Van der Sluis S, Kyvik KO, et al. Urticaria in monozygotic and dizygotic twins. *Journal*  
33  
34 522 *of allergy* 2012;2012  
35  
36 523 64. Hu Y, Chen Y, Liu S, et al. Breastfeeding duration modified the effects of neonatal and familial risk  
37  
38 524 factors on childhood asthma and allergy: a population-based study. *Respiratory research*  
39  
40 525 2021;22(1):1-11.  
41  
42  
43 526 65. Kolkhir P, Giménez-Arnau AM, Kulthanan K, et al. Urticaria. *Nature Reviews Disease Primers*  
44  
45 527 2022;8(1):61.  
46  
47  
48 528 66. Gabrielle P, Hashim MJ, Shaughnessy C, et al. Global epidemiology of urticaria: increasing burden  
49  
50 529 among children, females and low-income regions. *Acta Dermato-Venereologica* 2021;101(4)  
51  
52 530 67. Australian Indigenous HealthInfoNet. Summary of respiratory diseases among Aboriginal and  
53  
54 531 Torres Strait Islander children *Perth, WA Australian Indigenous HealthInfoNet*  
55  
56 532 *healthinfoNetCueDuau/respiratory* 2022  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES)

- 1  
2  
3 533 68. Perry TT, Grant TL, Dantzer JA, et al. Impact of socioeconomic factors on allergic diseases. *Journal*  
4  
5 534 *of Allergy and Clinical Immunology* 2023  
6  
7  
8 535  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure Legends**

**Figure 1.** Incidence of both asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

**Figure 2.** Separate incidence of asthma and allergic disease-related Emergency Department presentations in Central Queensland between 2018 and 2023  
ED= Emergency Department

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES).

**Table 1.** Background characteristics of patients presenting with asthma and allergic diseases compared to individuals presenting to ED for other reasons (N=813112)

Variable	Asthma and allergic disease-related ED presentations		P value
	No	Yes	
Indigenous status (n=812995)			
First Nations Australians	107099 (98.4)	1755 (1.6)	0.569
Australians of other descent /Not Stated	692623 (98.4)	11518 (1.6)	
Sex			
Female	397513 (98.2)	7395 (1.8)	< 0.001
Male	402219 (98.6)	5879 (1.4)	
Intersex	106 (100.0)	0 (0.0)	
Age group (Year, n=813111)			
≤4	78484 (97.5)	2018 (2.5)	< 0.001
5-14	87248 (97.2)	2540 (2.8)	
15-29	180778 (98.4)	2905 (1.6)	
30-44	148,015 (98.5)	2285 (1.5)	
45-59	129214 (98.4)	2051 (1.6)	
60+	176,098 (99.2)	1475 (0.8)	
Hospital			
Baralaba	1234(98.9)	14(1.1)	<0.001
Biloela	41009(98.0)	853(2.0)	
Blackwater	25048 (98.1)	474 (1.9)	
Emerald	83599(98.6)	1216 (1.4)	
Gladstone	203136(98.2)	3618(1.8)	
Mount Morgan	15972(98.1)	301(1.9)	
Moura	12457(98.1)	241(1.9)	
Rockhampton	298827(98.6)	4311(1.4)	
Springsure	7983(98.2)	144(1.8)	
Theodore	1414(98.7)	19(1.3)	
Woorabinda	12894(98.2)	239(1.8)	
Yeppoon	96265(98.1)	1844(1.9)	

ED= Emergency Department

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

551 **Table 2.** Incidence rate of asthma and allergic diseases from 2018 to 2023.

Asthma and allergic diseases	Asthma and specific type of allergy (per 10000 person-year with 95% CI)		
	First Nations Australians	Australians of other descent	Overall
Asthma*	87.8 (82.0, 93.8)	40.2 (39.0, 41.3)	40.5 (39.4, 41.5)
Unspecified allergy*	55.3 (50.8, 60.2)	36.0 (34.9, 37.1)	34.6 (33.6, 35.6)
Atopic/allergic contact dermatitis*	17.1 (14.6, 19.9)	10.6 (10.0, 11.2)	10.3 (9.7, 10.8)
Anaphylaxis and anaphylactic shock	7.2 (5.6, 9.1)	6.2 (5.7, 6.6)	5.8 (5.4, 6.2)
Allergic urticaria*	4.0 (2.9, 5.5)	2.3 (2.1, 2.6)	2.3 (2.0, 2.5)
Allergic conjunctivitis*	3.6 (2.5, 5.0)	2.4 (2.1, 2.7)	2.3 (2.1, 2.6)
Allergic rhinitis*	1.9 (1.2, 3.0)	0.7 (0.6, 0.9)	0.8 (0.6, 0.9)
Allergic purpura	0.5 (0.2, 1.2)	0.5 (0.4, 0.7)	0.5 (0.4,0.6)
Overall allergic diseases*, **	89.7 (83.9, 95.8)	58.8 (57.4, 60.2)	56.4 (55.2, 57.7)


552 \*P value < 0.05 when comparing the incidence rate per person-year between First Nations Australians  
553 and Australians of other descent, \*\*Overall allergic diseases encompass all specific allergic diseases,  
554 including unspecified allergy, atopic/allergic contact dermatitis, anaphylaxis, and anaphylactic shock,  
555 allergic urticaria, allergic conjunctivitis, allergic rhinitis, and allergic purpura but not asthma

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Enseignement Supérieur (ABES) .


**Table 3.** Incidence of asthma and allergic disease-related ED presentations (per 10,000 person-years) from 2018 to 2023


Year	Asthma and allergic disease-related ED presentations							
	Sex*		Age (Year)					
	Female	Male	0-4	5-14	15-29	30-44	45-59	60+
2018	101.2	78.2	281.6	111.9	99.0	75.0	64.5	47.9
2019	116.7	89.4	262.6	147.8	119.0	77.5	82.5	55.4
2020	105.4	80.7	208.9	105.0	108.9	98.3	80.5	44.7
2021	123.6	97.2	240.7	134.2	138.5	100.1	95.3	57.0
2022	111.9	86.9	222.3	134.2	135.6	84.2	74.5	46.3
2023	96.6	76.9	208.2	133.0	97.4	76.6	60.9	44.5
IRR (95% CI)	0.99 (0.95, 1.04)	1.001 (0.951, 1.053)	0.94 (0.91, 0.97)	1.02 (0.97, 1.06)	1.02 (0.97, 1.06)	1.01 (0.96, 1.06)	0.98 (0.93, 1.04)	0.98 (0.91, 1.05)
P value	0.824	0.974	<0.001	0.320	0.432	0.700	0.710	0.587

ED= Emergency Department, IRR= Incidence rate ratio, CI= Confidence interval, \*Intersex is not included in this table, as no cases of asthma or allergic disease were reported, as shown in Table 1.









**Supplemental Figure 1.** Locator map of the study area.

**Source:** The map was developed using the digital boundary files from the Australian Bureau of Statistics.

**Supplemental Table 1.** ICD-10-AM codes related to allergic conditions.

Condition	ICD-10-AM Code
Allergy, unspecified	T78.4, Z91.0
Allergic atopic dermatitis	L20, L20.8, L20.9
Allergic contact dermatitis	L23, L23.0-L23.9
Allergic conjunctivitis	H10.1, H10.2, H10.3, H10.4,
Allergic gastroenteritis	K52.2
Allergic purpura	D69.0
Allergic rhinitis	J30, J30.1, J30.2, J30.3, J30.4, J30.5
Allergic urticaria	L50.0, L50.8
Anaphylaxis	T78.0, T78.1, T78.2, T80.5, T88.6
Asthma	J45.0, J45.8, J45.9, J46
Food allergy	Y37.0-Y37.9, Y37.2, Y37.20, Y37.21, Y37.22, Y37.23, Y37.29, Y37.3, Y37.30, Y37.31, Y37.32, Y37.39, Y37.4, Y37.5

**Supplemental Table 2.** Emergency Department presentations at Public Hospitals in Central Queensland, 1 January 2018 to 30 November 2023 (N=813, 122)

Hospital	Year Frequency (%)						Total
	2018	2019	2020	2021	2022	2023	
Baralaba	X	X	X	237 (19.0)	547 (43.8)	464 (37.2)	1248 (100.0)
Biloela	6549 (15.6)	6394 (15.3)	7312 (17.5)	7268 (17.4)	7294 (17.4)	7045 (16.8)	41862 (100.0)
Blackwater	1207 (4.7)	5184 (20.3)	4453 (17.5)	4651 (18.2)	4752 (18.6)	5275 (20.7)	25522 (100.0)
Emerald	12320 (14.5)	13129 (15.5)	13110 (15.5)	16036 (18.9)	15639 (18.4)	1458 (17.2)	84815 (100.0)
Gladstone	31065 (15.0)	34340 (16.6)	36627 (17.7)	36349 (17.6)	36209 (17.5)	32164 (15.6)	206754 (100.0)
Mount Morgan	805 (4.9)	2925 (18.0)	2820 (17.3)	3280 (20.2)	3448 (21.2)	2995 (18.4)	16273 (100.0)
Moura	481 (3.8)	2158 (17.0)	2410 (19.0)	3118 (24.5)	2603 (20.5)	1928 (15.2)	12698 (100.0)
Rockhampton	47270 (15.5)	50522 (16.7)	49869 (16.5)	55777 (18.4)	52708 (17.4)	46992 (15.5)	303138 (100.0)
Springsure	337 (4.1)	1565 (19.3)	1697 (20.9)	1644 (20.2)	1535 (18.9)	1349 (16.6)	8127 (100.0)
Theodore	X	X	X	290 (20.2)	586 (40.9)	557 (38.9)	1433 (100.0)
Woorabinda	380 (2.9)	2107 (16.0)	2497 (19.0)	2476 (18.9)	2903 (22.1)	2770 (21.1)	13133 (100.0)
Yeppoon	14540 (14.8)	15017 (15.3)	15500 (15.8)	19797 (20.2)	17577 (17.9)	15678 (16.0)	98109 (100.0)
Total	114954 (14.1)	133341 (16.4)	136295 (16.8)	150923 (18.6)	145801 (17.9)	131798 (16.2)	813112 (100.0)

X= ED services were not available.